<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?subarticle ppat.1009965.r001?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Pathog</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLoS Pathogens</journal-title></journal-title-group><issn pub-type="ppub">1553-7366</issn><issn pub-type="epub">1553-7374</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8535176</article-id><article-id pub-id-type="pmid">34637487</article-id><article-id pub-id-type="doi">10.1371/journal.ppat.1009965</article-id><article-id pub-id-type="publisher-id">PPATHOGENS-D-21-01413</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Actinobacteria</subject><subj-group><subject>Mycobacterium Tuberculosis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Animal Studies</subject><subj-group><subject>Experimental Organism Systems</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Animal Studies</subject><subj-group><subject>Experimental Organism Systems</subject><subj-group><subject>Animal Models</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug Screening</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aliphatic Amino Acids</subject><subj-group><subject>Leucine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aliphatic Amino Acids</subject><subj-group><subject>Leucine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aliphatic Amino Acids</subject><subj-group><subject>Leucine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Animal Studies</subject><subj-group><subject>Animal Models of Disease</subject><subj-group><subject>Animal Models of Infection</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Animal Models of Infection</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aliphatic Amino Acids</subject><subj-group><subject>Valine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aliphatic Amino Acids</subject><subj-group><subject>Valine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aliphatic Amino Acids</subject><subj-group><subject>Valine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Animal Studies</subject><subj-group><subject>Experimental Organism Systems</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Zebrafish</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Zebrafish</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Animal Studies</subject><subj-group><subject>Experimental Organism Systems</subject><subj-group><subject>Animal Models</subject><subj-group><subject>Zebrafish</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Eukaryota</subject><subj-group><subject>Animals</subject><subj-group><subject>Vertebrates</subject><subj-group><subject>Fish</subject><subj-group><subject>Osteichthyes</subject><subj-group><subject>Zebrafish</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Zoology</subject><subj-group><subject>Animals</subject><subj-group><subject>Vertebrates</subject><subj-group><subject>Fish</subject><subj-group><subject>Osteichthyes</subject><subj-group><subject>Zebrafish</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Efficacy of epetraborole against <italic toggle="yes">Mycobacterium abscessus</italic> is increased with norvaline</article-title><alt-title alt-title-type="running-head">Epetraborole plus norvaline for <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic></alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8864-8949</contrib-id><name><surname>Sullivan</surname><given-names>Jaryd R.</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Formal analysis</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Methodology</role><role content-type="https://casrai.org/credit/">Visualization</role><role content-type="https://casrai.org/credit/">Writing &#x02013; original draft</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4777-0497</contrib-id><name><surname>Lupien</surname><given-names>Andr&#x000e9;anne</given-names></name><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Supervision</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8420-3320</contrib-id><name><surname>Kalthoff</surname><given-names>Elias</given-names></name><role content-type="https://casrai.org/credit/">Formal analysis</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Methodology</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0189-3504</contrib-id><name><surname>Hamela</surname><given-names>Claire</given-names></name><role content-type="https://casrai.org/credit/">Formal analysis</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Methodology</role><role content-type="https://casrai.org/credit/">Visualization</role><xref rid="aff006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Lorne</given-names></name><role content-type="https://casrai.org/credit/">Formal analysis</role><role content-type="https://casrai.org/credit/">Investigation</role><xref rid="aff007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Munro</surname><given-names>Kim A.</given-names></name><role content-type="https://casrai.org/credit/">Investigation</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8061-0436</contrib-id><name><surname>Schmeing</surname><given-names>T. Martin</given-names></name><role content-type="https://casrai.org/credit/">Resources</role><role content-type="https://casrai.org/credit/">Supervision</role><role content-type="https://casrai.org/credit/">Visualization</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6604-4458</contrib-id><name><surname>Kremer</surname><given-names>Laurent</given-names></name><role content-type="https://casrai.org/credit/">Resources</role><role content-type="https://casrai.org/credit/">Supervision</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="aff008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0402-4467</contrib-id><name><surname>Behr</surname><given-names>Marcel A.</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Funding acquisition</role><role content-type="https://casrai.org/credit/">Project administration</role><role content-type="https://casrai.org/credit/">Resources</role><role content-type="https://casrai.org/credit/">Supervision</role><role content-type="https://casrai.org/credit/">Writing &#x02013; original draft</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff009" ref-type="aff">
<sup>9</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Microbiology &#x00026; Immunology, McGill University, Montr&#x000e9;al, Canada</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montr&#x000e9;al, Canada</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>McGill International TB Centre, Montr&#x000e9;al, Canada</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Biochemistry, McGill University, Montr&#x000e9;al, Canada</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Centre de Recherche en Biologie Structural, McGill University, Montr&#x000e9;al, Canada</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Centre National de la Recherche Scientifique UMR 9004, Institut de Recherche en Infectiologie de Montpellier (IRIM), Universit&#x000e9; de Montpellier, Montpellier, France</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Clinical Proteomics Platform, Research Institute of the McGill University Health Centre, Montr&#x000e9;al, Canada</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>INSERM, IRIM, Montpellier, France</addr-line></aff><aff id="aff009"><label>9</label>
<addr-line>Department of Medicine, McGill University Health Centre, Montr&#x000e9;al, Canada</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Boshoff</surname><given-names>Helena Ingrid</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>National Institutes of Health, UNITED STATES</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>marcel.behr@mcgill.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2021</year></pub-date><volume>17</volume><issue>10</issue><elocation-id>e1009965</elocation-id><history><date date-type="received"><day>6</day><month>7</month><year>2021</year></date><date date-type="accepted"><day>23</day><month>9</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 Sullivan et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Sullivan et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="ppat.1009965.pdf"/><abstract><p><italic toggle="yes">Mycobacterium abscessus</italic> is the most common rapidly growing non-tuberculous mycobacteria to cause pulmonary disease in patients with impaired lung function such as cystic fibrosis. <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> displays high intrinsic resistance to common antibiotics and inducible resistance to macrolides like clarithromycin. As such, <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> is clinically resistant to the entire regimen of front-line <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> drugs, and treatment with antibiotics that do inhibit <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> in the lab results in cure rates of 50% or less. Here, we identified epetraborole (EPT) from the MMV pandemic response box as an inhibitor against the essential protein leucyl-tRNA synthetase (LeuRS) in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>. EPT protected zebrafish from lethal <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infection and did not induce self-resistance nor against clarithromycin. Contrary to most antimycobacterials, the whole-cell activity of EPT was greater against <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> than <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic>, but crystallographic and equilibrium binding data showed that EPT binds LeuRS<sub>Mabs</sub> and LeuRS<sub>Mtb</sub> with similar residues and dissociation constants. Since EPT-resistant <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> mutants lost LeuRS editing activity, these mutants became susceptible to misaminoacylation with leucine mimics like the non-proteinogenic amino acid norvaline. Proteomic analysis revealed that when <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS mutants were fed norvaline, leucine residues in proteins were replaced by norvaline, inducing the unfolded protein response with temporal changes in expression of GroEL chaperonins and Clp proteases. This supports our <italic toggle="yes">in vitro</italic> data that supplementation of media with norvaline reduced the emergence of EPT mutants in both <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> and <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic>. Furthermore, the combination of EPT and norvaline had improved <italic toggle="yes">in vivo</italic> efficacy compared to EPT in a murine model of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infection. Our results emphasize the effectiveness of EPT against the clinically relevant cystic fibrosis pathogen <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>, and these findings also suggest norvaline adjunct therapy with EPT could be beneficial for <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> and other mycobacterial infections like tuberculosis.</p></abstract><abstract abstract-type="summary"><title>Author summary</title><p>Current antimycobacterial drugs are inadequate to handle the increasing number of non-tuberculous mycobacteria infections that eclipse tuberculosis infections in many developed countries. Of particular importance for cystic fibrosis patients, <italic toggle="yes">Mycobacterium abscessus</italic> is notoriously difficult to treat where patients spend extended time on antibiotics with cure rates comparable to extreme drug resistant <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic>. Here, we identified epetraborole (EPT) with <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> activities against <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>. We showed that EPT targets the editing domain of the leucyl-tRNA synthetase (LeuRS) and that escape mutants lost LeuRS editing activity, making these mutants susceptible to misaminoacylation with leucine mimics. Most importantly, combination therapy of EPT and norvaline limited the rate of EPT resistance in both <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> and <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic>, and this was the first study to demonstrate improved <italic toggle="yes">in vivo</italic> efficacy of EPT and norvaline compared to EPT in a murine model of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> pulmonary infection. The demonstration of norvaline adjunct therapy with EPT for <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infections is promising for cystic fibrosis patients and could translate to other mycobacterial infections, such as tuberculosis.</p></abstract><funding-group><award-group id="award001"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000082</institution-id><institution>Cystic Fibrosis Canada</institution></institution-wrap>
</funding-source><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8864-8949</contrib-id>
<name><surname>Sullivan</surname><given-names>Jaryd R.</given-names></name>
</principal-award-recipient></award-group><award-group id="award002"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100014131</institution-id><institution>McGill University Health Centre</institution></institution-wrap>
</funding-source><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8864-8949</contrib-id>
<name><surname>Sullivan</surname><given-names>Jaryd R.</given-names></name>
</principal-award-recipient></award-group><award-group id="award003"><funding-source>
<institution>Harrison Watson Fellowship</institution>
</funding-source><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8864-8949</contrib-id>
<name><surname>Sullivan</surname><given-names>Jaryd R.</given-names></name>
</principal-award-recipient></award-group><award-group id="award004"><funding-source>
<institution>Structure-Guided Drug Discovery Coalition</institution>
</funding-source><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0402-4467</contrib-id>
<name><surname>Behr</surname><given-names>Marcel A.</given-names></name>
</principal-award-recipient></award-group><award-group id="award005"><funding-source>
<institution>cihr</institution>
</funding-source><award-id>FDN&#x02013;148362</award-id><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0402-4467</contrib-id>
<name><surname>Behr</surname><given-names>Marcel A.</given-names></name>
</principal-award-recipient></award-group><award-group id="award006"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100006342</institution-id><institution>association vaincre la mucoviscidose</institution></institution-wrap>
</funding-source><award-id>RF20200502678</award-id><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6604-4458</contrib-id>
<name><surname>Kremer</surname><given-names>Laurent</given-names></name>
</principal-award-recipient></award-group><award-group id="award007"><funding-source>
<institution>Association Gregory Lemarchal</institution>
</funding-source><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6604-4458</contrib-id>
<name><surname>Kremer</surname><given-names>Laurent</given-names></name>
</principal-award-recipient></award-group><funding-statement>This work was funded by Cystic Fibrosis Canada (to J.R.S. and M.A.B.), the Research Institute of the McGill University Health Centre (to J.R.S.), the Harrison Watson Fellowship (to J.R.S.), the Structure-guided Drug Discovery Coalition (to M.A.B.), CIHR operating grant (to M.A.B.) and was supported by Vaincre la Mucoviscidose (RF20200502678) (to L.K) and the Association Gregory Lemarchal (to L.K). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="8"/><table-count count="2"/><page-count count="28"/></counts><custom-meta-group><custom-meta><meta-name>PLOS Publication Stage</meta-name><meta-value>vor-update-to-uncorrected-proof</meta-value></custom-meta><custom-meta><meta-name>Publication Update</meta-name><meta-value>2021-10-22</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its <xref rid="sec034" ref-type="sec">Supporting Information</xref> files. Structures have been deposited on PDB under accession codes 7N11 and 7N12. Sequence data has been deposited in the NCBI Sequence Read Archive under the NCBI BioProject ID PRJNA756101. (<ext-link xlink:href="https://www.ncbi.nlm.nih.gov/sra/X" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/sra/X</ext-link>).</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its <xref rid="sec034" ref-type="sec">Supporting Information</xref> files. Structures have been deposited on PDB under accession codes 7N11 and 7N12. Sequence data has been deposited in the NCBI Sequence Read Archive under the NCBI BioProject ID PRJNA756101. (<ext-link xlink:href="https://www.ncbi.nlm.nih.gov/sra/X" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/sra/X</ext-link>).</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p><italic toggle="yes">Mycobacterium abscessus</italic> is a nontuberculous mycobacterium that commonly causes chronic lung disease, especially among patients with cystic fibrosis [<xref rid="ppat.1009965.ref001" ref-type="bibr">1</xref>]. Treatment of pulmonary exacerbation relies on a regimen of intravenous amikacin (AMK), tigecycline, and imipenem plus an oral macrolide if the isolate is susceptible to macrolides [<xref rid="ppat.1009965.ref002" ref-type="bibr">2</xref>,<xref rid="ppat.1009965.ref003" ref-type="bibr">3</xref>]. Despite guideline-based treatment, combination therapy typically results in cure rates of 50% or less due to the bacterium being intrinsically resistant to many antibiotic classes [<xref rid="ppat.1009965.ref004" ref-type="bibr">4</xref>,<xref rid="ppat.1009965.ref005" ref-type="bibr">5</xref>]. Unfortunately, the <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> drug-development pipeline is limited to a handful of repurposed drugs (clofazimine, rifabutin, and bedaquiline) [<xref rid="ppat.1009965.ref006" ref-type="bibr">6</xref>]. Lately, antibiotics that have shown activity in pre-clinical studies include the oxazolidinones (LCB01-0371 [<xref rid="ppat.1009965.ref007" ref-type="bibr">7</xref>] and tedizolid [<xref rid="ppat.1009965.ref008" ref-type="bibr">8</xref>]) that target the 50S ribosomal subunit and PIPD1/indol-2-carboxamides that target the mycolic acid transporter MmpL3 [<xref rid="ppat.1009965.ref009" ref-type="bibr">9</xref>,<xref rid="ppat.1009965.ref010" ref-type="bibr">10</xref>].</p><p>Recently, aminoacyl-tRNA synthetases (aaRSs) became targets of interest for drug discovery when benzoxaboroles were identified as novel boron-based pharmacophores [<xref rid="ppat.1009965.ref011" ref-type="bibr">11</xref>,<xref rid="ppat.1009965.ref012" ref-type="bibr">12</xref>]. aaRSs are enzymes that aminoacylate tRNAs with their cognate amino acids. All aaRSs have an aminoacylation domain while some are bifunctional and contain an editing domain. The aminoacylation domain forms an aminoacyl adenylate through condensation of the amino acid with ATP, and then transfers the aminoacyl moiety to the 3&#x02019; terminal adenosine of the tRNA acceptor stem. Some aaRSs, however, have evolved an editing domain to ensure the correct amino acid is ligated to its tRNA [<xref rid="ppat.1009965.ref013" ref-type="bibr">13</xref>,<xref rid="ppat.1009965.ref014" ref-type="bibr">14</xref>]. This domain is critical for aaRSs that must distinguish their cognate amino acid from structurally similar amino acids like branched-chain amino acids. Leucyl-tRNA synthetases (LeuRSs) are examples of aaRSs that rely on their editing domains to limit misaminoacylation of tRNA with near-cognate amino acids and maintain the fidelity of the genetic code.</p><p>Herein, we identified epetraborole (EPT) from the Medicines for Malaria Venture (MMV) Open pandemic response box as a LeuRS inhibitor in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> with nanomolar activity <italic toggle="yes">in vitro</italic> and activity in zebrafish embryos and NOD.SCID mice. Interestingly, EPT was more active against <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> than <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic>, and this observation was not supported by structural differences in the crystal structures of the LeuRS editing domain of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> and <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> bound to EPT. Furthermore, we highlighted the utility of norvaline to target LeuRS editing deficient escape mutants and suppress resistance <italic toggle="yes">in vitro</italic> by misincorporation of norvaline in place of leucine residues resulting in disrupted protein folding. Importantly, we showed that EPT and norvaline combination has improved efficacy over EPT monotherapy in a murine model of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infection. These data support the potential of the benzoxaborole scaffold in the antimycobacterial drug pipeline and suggest that its activity can be potentiated by supplementation with norvaline or a norvaline derivative.</p></sec><sec sec-type="results" id="sec002"><title>Results</title><sec id="sec003"><title>Discovery of an antimycobacterial inhibitor against <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic></title><p>To identify compounds with antimycobacterial activity, we first engineered a luminescent <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977 strain which constitutively expressed the <italic toggle="yes">luxCDABE</italic> operon [<xref rid="ppat.1009965.ref015" ref-type="bibr">15</xref>] (<italic toggle="yes">M</italic>. <italic toggle="yes">abscessus lux</italic>). We then screened the 176 compound open-library provided by GlaxoSmithKline (<xref rid="ppat.1009965.s001" ref-type="supplementary-material">S1A&#x02013;S1C Fig</xref>) and the 400 compound Pathogen and Pandemic Response Boxes from MMV (<xref rid="ppat.1009965.s001" ref-type="supplementary-material">S1D&#x02013;S1F Fig</xref>) using a threshold &#x02265; 90% reduction in luminescence compared to non-treated bacteria at 10 &#x003bc;M. Primary hits (20 compounds) were tested in a secondary screen using the resazurin microtiter assay (REMA) at 10 &#x003bc;M on the <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977 strain. Secondary hits (9 compounds) were then tested in a dose-response assay on <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977 from a fresh solid compound to determine MIC<sub>90</sub>. The HepG2 (human hepatocytes) cell line was used to assess the toxicity of hits. Among three compounds (0.3% positive hits of 976 compounds) from the pandemic response box that satisfied primary and secondary criteria, we identified EPT (<xref rid="ppat.1009965.g001" ref-type="fig">Fig 1A</xref>) as having the most potent antimycobacterial activity and highest therapeutic index (<xref rid="ppat.1009965.t001" ref-type="table">Table 1</xref>, MIC<sub>90</sub> 0.23 &#x003bc;M (0.063 &#x003bc;g/mL), TI (TD<sub>50</sub>/MIC<sub>90</sub>) EPT &#x0003e; 330). It was previously reported in <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> that potent <italic toggle="yes">in vitro</italic> growth inhibitors could display carbon-source-dependent effects, which leads to a loss of activity when advanced into <italic toggle="yes">in vivo</italic> models [<xref rid="ppat.1009965.ref016" ref-type="bibr">16</xref>]. We thus measured the MIC<sub>90</sub> of EPT on different carbon sources (glycerol vs acetate), in the presence or absence of the detergent Tween-80, and in different nutrient bases (Middlebrook 7H9 vs cation-adjusted Mueller-Hinton). EPT was active in all assayed growth conditions but lost potency in cation-adjusted Mueller Hinton (CaMH) media (<xref rid="ppat.1009965.s006" ref-type="supplementary-material">S1 Table</xref>). Lower activity of EPT in CaMH media is unsurprising as it was previously shown that rifamycins [<xref rid="ppat.1009965.ref017" ref-type="bibr">17</xref>] as well as other antimicrobials [<xref rid="ppat.1009965.ref018" ref-type="bibr">18</xref>] lose activity in CaMH media (0.5mg/L Ca<sup>2+</sup> and 0.05mg/L Mg<sup>2+</sup> in 7H9; 20-25mg/L Ca<sup>2+</sup> and 10&#x02013;12.5mg/L Mg<sup>2+</sup> in CaMH). It is thought that some antimicrobials may chelate divalent metal ions, thus limiting their uptake in cells.</p><fig position="float" id="ppat.1009965.g001"><object-id pub-id-type="doi">10.1371/journal.ppat.1009965.g001</object-id><label>Fig 1</label><caption><title>EPT <italic toggle="yes">in vitro</italic> activity against <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>.</title><p><bold>A</bold> Structure of EPT. <bold>B</bold> Epetraborole kill kinetics of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus in vitro</italic>. Bacteria were incubated in 7H9 complete with drug-free (black circles), AMK 20X MIC<sub>90</sub> (blue squares, 80 &#x003bc;g/mL), RIF 20X MIC<sub>90</sub> (red triangles, 60 &#x003bc;g/mL), EPT 20X MIC<sub>90</sub> (yellow hexagons, 1.6 &#x003bc;g/mL), EPT 40X MIC<sub>90</sub> (orange diamonds, 3.2 &#x003bc;g/mL), or EPT 80X MIC<sub>90</sub> (brown inverted triangles, 6.4 &#x003bc;g/mL). The dashed red line indicates 99.9% or 3 log<sub>10</sub> reduction in CFU/mL threshold of a bactericidal drug. Data shown is mean &#x000b1; SD of three independent experiments. <bold>C</bold> MIC<sub>90</sub> from induced cultures relative to drug free conditions. Bacteria were grown to OD<sub>600</sub> 0.05 and induced with no drug (white), 0.016 &#x003bc;g/mL CLR (yellow), 0.016 &#x003bc;g/mL EPT (blue). After 24 hours (left) or 14 days (right) of induction, cultures were passaged for 6 days in drug free media (dotted bars). Data shown is mean &#x000b1; SD from three independent experiments. Error bars for drug free data derived from MIC<sub>90</sub> / MIC<sub>90</sub> average from three or six replicates. *, p = 0.02; **, p = 0.0017; ****, p = 0.0005 by one-way ANOVA with Tukey&#x02019;s multiple comparisons test.</p></caption><graphic xlink:href="ppat.1009965.g001" position="float"/></fig><table-wrap position="float" id="ppat.1009965.t001"><object-id pub-id-type="doi">10.1371/journal.ppat.1009965.t001</object-id><label>Table 1</label><caption><title>MMV Open pandemic response box hits and reference compounds.</title></caption><alternatives><graphic xlink:href="ppat.1009965.t001" id="ppat.1009965.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" style="background-color:#D9D9D9" colspan="1">Parameter</th><th align="center" colspan="5" style="background-color:#D9D9D9" rowspan="1">Compound</th></tr><tr><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">EPT</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">ERV</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">IQN</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">BDQ</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">AMK</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MIC<sub>90</sub> (&#x003bc;g/mL)</td><td align="left" rowspan="1" colspan="1">0.063</td><td align="left" rowspan="1" colspan="1">1.9</td><td align="left" rowspan="1" colspan="1">3.3</td><td align="left" rowspan="1" colspan="1">0.67</td><td align="left" rowspan="1" colspan="1">4.0</td></tr><tr><td align="left" rowspan="1" colspan="1">TD<sub>50</sub> (&#x003bc;g/mL)</td><td align="left" rowspan="1" colspan="1">&#x0003e;27</td><td align="left" rowspan="1" colspan="1">&#x0003e;63</td><td align="left" rowspan="1" colspan="1">&#x0003e;39</td><td align="left" rowspan="1" colspan="1">9.4<xref rid="t001fn002" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">TI (TD<sub>50</sub>/MIC<sub>90</sub>)</td><td align="left" rowspan="1" colspan="1">&#x0003e;430</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">4.5</td></tr><tr><td align="left" rowspan="1" colspan="1">MW (g/mol)</td><td align="left" rowspan="1" colspan="1">237.06</td><td align="left" rowspan="1" colspan="1">631.52</td><td align="left" rowspan="1" colspan="1">393.40</td><td align="left" rowspan="1" colspan="1">555.51</td><td align="left" rowspan="1" colspan="1">585.60</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>EPT, Epetraborole; ERV, Eravacycline; IQN, Isoquinoline urea; BDQ, Bedaquiline; AMK, Amikacin; MIC<sub>90</sub>, concentration of drug that inhibits 90% of bacterial growth; TD<sub>50</sub>, concentration of drug with 50% toxicity against HepG2 cell line. TI, therapeutic index.</p></fn><fn id="t001fn002"><p><sup>a</sup>Data from Lupien, A et al. <italic toggle="yes">Antimicrob Agents Chemother</italic>. <bold>2018</bold></p></fn></table-wrap-foot></table-wrap><p>Next, we tested the <italic toggle="yes">in vitro</italic> activity of EPT against a panel of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> clinical isolates belonging to the three subspecies of the <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> complex (<italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>, <italic toggle="yes">M</italic>. <italic toggle="yes">massiliense</italic>, and <italic toggle="yes">M</italic>. <italic toggle="yes">bolletii</italic>) with smooth and rough colony morphologies and with different drug susceptibility profiles to various antibiotics. There was no loss in activity against clinical isolates (range of 0.014&#x02013;0.046 &#x003bc;g/mL) nor different morphologies (<xref rid="ppat.1009965.s007" ref-type="supplementary-material">S2 Table</xref>). To determine the spectrum of activity of EPT, we curated a panel of various mycobacteria and representative gram-positive and gram-negative bacteria. Interestingly, EPT appears to be more selective for <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> with lower activity against <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> H37Rv (<xref rid="ppat.1009965.s008" ref-type="supplementary-material">S3 Table</xref>). <italic toggle="yes">In vitro</italic> growth kill kinetics indicated that EPT is bacteriostatic against <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> as previously demonstrated against <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> [<xref rid="ppat.1009965.ref019" ref-type="bibr">19</xref>], while 10% of CFUs were lost at 24 hours with AMK and rifampicin (RIF) at 20X MIC<sub>90</sub>. Interestingly, these two antimycobacterial agents with bactericidal action against other mycobacteria lose this ability when targeting <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> (<xref rid="ppat.1009965.g001" ref-type="fig">Fig 1B</xref>) [<xref rid="ppat.1009965.ref020" ref-type="bibr">20</xref>].</p></sec><sec id="sec004"><title>Clinical considerations for EPT</title><p>Macrolides represent the cornerstone of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> therapy. However, macrolide susceptibility <italic toggle="yes">in vitro</italic> does not correlate with clinical outcome success due to point mutations at positions 2058 or 2059 in the 23S rRNA <italic toggle="yes">rrl</italic> gene (<italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> numbering), and inducible macrolide resistance conferred from the recently identified ribosomal methyltransferase <italic toggle="yes">erm</italic>(41) [<xref rid="ppat.1009965.ref021" ref-type="bibr">21</xref>,<xref rid="ppat.1009965.ref022" ref-type="bibr">22</xref>]. Nash et al (2009) discovered that <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> exhibited an inducible resistant phenotype to macrolides, like clarithromycin (CLR), during a 14-day incubation. To this extent, we asked if EPT induced self-resistance or cross-resistance to macrolides. To answer this question, we performed the inducible macrolide resistance assay where <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> was cultured with a subinhibitory concentration of CLR (0.016 &#x003bc;g/mL) or EPT (0.016 &#x003bc;g/mL) for 14 days. At 24 hours and 14 days, aliquots of culture were collected, and the MIC<sub>90</sub> of CLR and EPT was determined using REMA. Relative to drug-free conditions, <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> cultured with CLR displayed an increased MIC<sub>90</sub> to CLR while the EPT MIC<sub>90</sub> for bacteria exposed to EPT remained unchanged up to 14 days (<xref rid="ppat.1009965.g001" ref-type="fig">Fig 1C</xref> solid bars). To ensure the increased MIC<sub>90</sub> resulted from inducible resistance rather than the selection of spontaneous CLR and EPT resistant mutants, the cultures were passaged in antibiotic-free media for 6 additional days and the MIC<sub>90</sub> measurements were repeated. In the case of CLR resistance, the MIC<sub>90</sub> returned to baseline after the antibiotics were removed (<xref rid="ppat.1009965.g001" ref-type="fig">Fig 1C</xref> dotted bars). In addition, EPT stimulation did not result in cross-resistance to CLR, and CLR induction did not result in cross-resistance to EPT. The latter is an important finding with clinical significance because CLR is known to impart resistance to aminoglycoside antibiotics [<xref rid="ppat.1009965.ref023" ref-type="bibr">23</xref>].</p><p>Because <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infections require 18&#x02013;24 months of antibiotic courses, multidrug treatments are standard practice [<xref rid="ppat.1009965.ref002" ref-type="bibr">2</xref>,<xref rid="ppat.1009965.ref003" ref-type="bibr">3</xref>]. To ensure EPT would not hamper a multidrug regimen, we performed checkerboard assays with common antimycobacterial drugs. In the checkerboard assays, we used RIF/CLR and CLR/AMK as the synergy and antagonism controls, respectively [<xref rid="ppat.1009965.ref023" ref-type="bibr">23</xref>,<xref rid="ppat.1009965.ref024" ref-type="bibr">24</xref>]. We did not observe antagonism between EPT and various antimycobacterial agents that target a range of cellular processes (<xref rid="ppat.1009965.s002" ref-type="supplementary-material">S2 Fig</xref>). Whether EPT should be included in a multidrug regimen remains to be determined.</p></sec><sec id="sec005"><title>EPT protects zebrafish from <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infection</title><p>In order to investigate the <italic toggle="yes">in vivo</italic> activity of EPT, we used the embryonic zebrafish model of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infection, which has been developed to test the <italic toggle="yes">in vivo</italic> efficacy of drugs against <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> [<xref rid="ppat.1009965.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="ppat.1009965.ref027" ref-type="bibr">27</xref>]. Initial experiments indicated that EPT concentrations up to 40 &#x003bc;g/mL (final concentration in fish water) did not interfere with larval development and was well tolerated in embryos when treatment was applied for up to 5 days with daily drug renewal (<xref rid="ppat.1009965.g002" ref-type="fig">Fig 2A</xref>). Green fluorescent wasabi-expressing <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> (R variant) was microinjected in the caudal vein of embryos at 30 hours post-fertilization. EPT was directly added at 1 day post-infection to the water containing the infected embryos, with EPT-supplemented water changed on a daily basis for 5 days. Embryo survival was monitored and recorded daily for 11 days. While a slight increase in the survival rate was observed with 10 &#x003bc;g/mL EPT, this effect was significantly improved with 40 &#x003bc;g/mL EPT with a delay in larval mortality, as compared to the untreated group (<xref rid="ppat.1009965.g002" ref-type="fig">Fig 2B</xref>). The protection provided by EPT is maintained throughout the 5-day treatment course and was correlated with decreased bacterial burdens beginning 4 dpi demonstrated by fluorescent pixel counting (<xref rid="ppat.1009965.g002" ref-type="fig">Fig 2C and 2D</xref>). These results clearly indicate that EPT protects zebrafish from <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infection.</p><fig position="float" id="ppat.1009965.g002"><object-id pub-id-type="doi">10.1371/journal.ppat.1009965.g002</object-id><label>Fig 2</label><caption><title>EPT <italic toggle="yes">in vivo</italic> activity against <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>.</title><p><bold>A</bold> EPT toxicity against zebrafish embryos. Groups of uninfected embryos were immersed in water containing 10 to 50<italic toggle="yes">&#x003bc;</italic>g/mL EPT for 5 days. Red bar indicates duration of treatment. Data is from two independent experiments. <bold>B</bold> EPT <italic toggle="yes">in vivo</italic> activity in zebrafish embryos. Zebrafish embryos at 30 h postfertilization were infected with approximately 200 CFUs of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> expressing green fluorescent wasabi or PBS via caudal vein injection. At 1 dpi, embryos were randomly split into approximately 20 embryos per group and exposed to increasing concentrations of EPT (10 and 40 &#x003bc;g/mL) in fish water. Drugs were renewed at a daily basis for 5 days (red bar) after which embryos were washed twice in fresh embryo water and maintained in fish water. Each treatment group was compared against the untreated infected group with significant differences calculated using the log-rank (Mantel-Cox) statistical test for survival curves. Data shown are the merge of four independent experiments. *, p&#x02009; = 0.02; ***, p = 0.0007. <bold>C</bold> Fluorescent Pixel Counts (FPC) determination using the ImageJ software, reflecting the bacterial loads at 4 and 6 days post-infection (dpi). Each bar represents a pool of the average of normalized FPC from three independent experiments (n = 22 to 36 embryos). Error bars represent standard deviations. Statistical significance was determined using Welch&#x02019;s <italic toggle="yes">t</italic> test. **, p &#x02264; 0.0054. <bold>D</bold> Representative whole embryos from the untreated group (upper panels) and treated group (10 or 40 &#x003bc;g/mL EPT; lower panels) at 4 and 6 dpi. Green overlay represents <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> expressing wasabi. Scale bar, 200 &#x003bc;m.</p></caption><graphic xlink:href="ppat.1009965.g002" position="float"/></fig></sec><sec id="sec006"><title>EPT targets LeuRS in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic></title><p>Benzoxaboroles were shown to inhibit LeuRS in fungi, gram-negative pathogens and most recently <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> [<xref rid="ppat.1009965.ref011" ref-type="bibr">11</xref>,<xref rid="ppat.1009965.ref019" ref-type="bibr">19</xref>,<xref rid="ppat.1009965.ref028" ref-type="bibr">28</xref>]. To determine the target of EPT in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>, 10<sup>9</sup> CFUs were plated on solid media with 10X, 20X, or 40X MIC<sub>90</sub> of EPT to select EPT-resistant mutants. Control mutants were also selected on 40X MIC of AMK. Unlike the EPT resistance frequency of 4.8 x 10<sup>&#x02212;8</sup> in <italic toggle="yes">Pseudomonas aeruginosa</italic>, the resistance frequency was 10-fold lower in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> (<xref rid="ppat.1009965.s009" ref-type="supplementary-material">S4 Table</xref>, 2 x 10<sup>&#x02212;9</sup>) [<xref rid="ppat.1009965.ref028" ref-type="bibr">28</xref>]. The low <italic toggle="yes">in vitro</italic> resistance frequency to EPT is highlighted when compared to the control mutants against AMK (1.3 x 10<sup>&#x02212;8</sup>). In order to confirm that isolated resistant mutants were true mutants to EPT, we performed REMA using a panel of antimycobacterial agents on the four mutants (one selected on 10X, one on 20X, and two on 40X MIC<sub>90</sub> of EPT). We also screened one AMK mutant. As illustrated in <xref rid="ppat.1009965.s003" ref-type="supplementary-material">S3 Fig</xref>, the four EPT mutants were resistant up to 2.7 &#x003bc;g/mL EPT, while maintaining susceptibility to AMK, bedaquiline (BDQ), and RIF. Likewise, the AMK control mutant was only resistant to AMK.</p><p>Since benzoxaboroles are known to target LeuRSs, we used a focused approach to identify the mutation(s) in <italic toggle="yes">leuS</italic> that could be responsible for the observed EPT resistance. <italic toggle="yes">leuS</italic> was PCR amplified from gDNA from the four EPT mutants, and single-nucleotide polymorphisms (SNPs) were identified using Sanger sequencing (<xref rid="ppat.1009965.s010" ref-type="supplementary-material">S5 Table</xref>). In all four mutants, a G to C transversion at position 1306 was identified, which resulted in the conserved D436 residue critical for the catalysis of editing misaminoacylated tRNA<sup>Leu</sup> substituted for H436 (<xref rid="ppat.1009965.g003" ref-type="fig">Fig 3A and 3B</xref>) [<xref rid="ppat.1009965.ref029" ref-type="bibr">29</xref>]. This was further supported with whole-genome sequencing of the <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977 reference strain, one mutant isolated at 20X MIC, and one mutant isolated at 40X MIC. When compared to the reference strain, five variants were identified in the 20X mutant including a T to G transition at position 1261 in <italic toggle="yes">leuS</italic> which resulted in a Y421D substitution. Furthermore, the G to C transversion at position 1306 which lead to the D436H substitution was confirmed in the 40X mutant (<xref rid="ppat.1009965.s011" ref-type="supplementary-material">S6 Table</xref>). This contrasts with LeuRS variants identified in <italic toggle="yes">P</italic>. <italic toggle="yes">aeruginosa</italic> such as T323P, T327P, and V429M from Hernandez <italic toggle="yes">et al</italic>. or LeuRS variants such as T322I, D326N, A414V, and R435H identified in a phase 2 clinical trial for complicated urinary tract infections caused by <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> from O&#x02019;Dwyer <italic toggle="yes">et al</italic>. [<xref rid="ppat.1009965.ref028" ref-type="bibr">28</xref>,<xref rid="ppat.1009965.ref030" ref-type="bibr">30</xref>]. However, the phase 2 clinical trial did identify <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> isolates with a LeuRS D436A variant. (<italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> numbering). To verify the functional significance of the D436H substitution, the <italic toggle="yes">leuS</italic> genes from <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977 wildtype (EPT sensitive) and <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> containing the G1306C substitution (EPT-resistant) were cloned into the mycobacterial integrative vector pMV306 under the control of the constitutive <italic toggle="yes">hsp60</italic> promoter, yielding pMVhsp60_leuS<sup>D</sup> and pMVhsp60_leuS<sup>D436H</sup>. EPT-sensitive <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> was electroporated with pMVhsp60_leuS<sup>D</sup>, pMVhsp60_leuS<sup>D436H,</sup> or empty vector control. Only EPT sensitive <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> complemented with the mutant <italic toggle="yes">leuS</italic> (pMVhsp60_leuS<sup>D436H</sup>) and not the wildtype <italic toggle="yes">leuS</italic> (pMVhsp60_leuS<sup>D</sup>) had increased resistance to EPT (<xref rid="ppat.1009965.g003" ref-type="fig">Fig 3C</xref>). The integrative complement system using pMVhsp60 may not have provided a complete phenocopy of the true mutant when compared to the episomal equivalent. Also, <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> may not use the <italic toggle="yes">hsp60</italic> promoter from <italic toggle="yes">M</italic>. <italic toggle="yes">bovis</italic> with optimal efficiency. Lastly, the <italic toggle="yes">hsp60</italic> promoter may not operate with the same strength as the <italic toggle="yes">leuS</italic> promoter.</p><fig position="float" id="ppat.1009965.g003"><object-id pub-id-type="doi">10.1371/journal.ppat.1009965.g003</object-id><label>Fig 3</label><caption><title>EPT targets the editing domain of LeuRS in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>.</title><p><bold>A</bold> Domains of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS. Zinc domain, pink; editing domain, cyan; catalytic domain, grey; leucine-rich domain, green; anticodon-binding domain, purple; c-terminus, yellow. <bold>B</bold> Amino acid alignment of part of the editing domain of LeuRS <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977, EPT mutant, and reference mycobacteria. Non-consensus residues are in red. Genbank accession numbers: P9WFV1.1 (<italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic>) 11896261 (<italic toggle="yes">M</italic>. <italic toggle="yes">avium</italic>) 6224275 (<italic toggle="yes">M</italic>. <italic toggle="yes">marinum</italic>). <bold>C</bold> Dose-response curves of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977 (black circles), D436H mutant (red squares), <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> empty vector (white diamonds), <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> pMVhsp60_leuS (pink triangles) and <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> pMV306hsp60_leuSD436H (crosses). Data shown is mean &#x000b1; SD from one experiment representative of two. <bold>D</bold>
<italic toggle="yes">leuS</italic> is an essential gene in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> using CRISPRi gene knockdown. <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> carrying integrated empty CRISPRi vector (EV, circles), CRISPRi:<italic toggle="yes">mmpL4b</italic> as a non-essential gene control (squares), or CRISPRi:<italic toggle="yes">leuS</italic> (triangles) were grown with/without 0.01 &#x003bc;g/mL ATc. Data is mean &#x000b1; SD from biological triplicates. <bold>E</bold> MIC<sub>99</sub> to EPT and RFB in CRISPRi knockdown of <italic toggle="yes">leuS</italic> in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>. **, p = 0.005; ns, no statistical significance by one-way ANOVA with Dunnett&#x02019;s multiple comparisons test. Data shown is mean &#x000b1; SD from three biological replicates.</p></caption><graphic xlink:href="ppat.1009965.g003" position="float"/></fig><p>We showed that LeuRS<sup>D436H</sup> confers high-level resistance to EPT and that complementing the resistant allele into a wildtype background imparts resistance. As a complementary means of verifying the target, we adapted a CRISPR-interference (CRISPRi) system for gene knockdown in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> [<xref rid="ppat.1009965.ref031" ref-type="bibr">31</xref>]. CRISPRi facilitates gene knockdown using a guide RNA and catalytically inactive Cas9 endonuclease to sterically prevent transcription of a gene of interest when induced with anhydrotetracycline (ATc). We used CRISPRi to knockdown <italic toggle="yes">leuS</italic> which resulted in hyper susceptibility to EPT. Since <italic toggle="yes">leuS</italic> is an essential gene in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> (<xref rid="ppat.1009965.g003" ref-type="fig">Fig 3D</xref>), we used 10-fold and 20-fold less ATc than required for complete growth suppression when targeting an essential gene. The EPT MIC<sub>99</sub> of the strain induced with 0.1 &#x003bc;g/mL ATc decreased 10-fold compared to uninduced conditions, while induction did not affect the rifabutin (RFB) MIC<sub>99</sub> (<xref rid="ppat.1009965.g003" ref-type="fig">Fig 3E</xref>). These results provide further evidence that EPT targets LeuRS in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>.</p></sec><sec id="sec007"><title>EPT binds the editing active site of LeuRS</title><p>Although EPT is active against <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> and <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic>, the MIC<sub>90</sub> for <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> whole-cell activity is 7-fold lower (MIC<sub>90Mabs</sub> 0.063 &#x003bc;g/mL vs MIC<sub>90Mtb</sub> 0.46 &#x003bc;g/mL). We hypothesized that EPT had a higher affinity for the <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS editing active site. We therefore performed binding studies between EPT and the editing domains of LeuRS from <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> and <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> using isothermal titration calorimetry (ITC) (<xref rid="ppat.1009965.s004" ref-type="supplementary-material">S4 Fig</xref>). <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS and <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> LeuRS contain a single binding site for EPT, and we obtained similar equilibrium dissociation constants and Gibbs free energies (<xref rid="ppat.1009965.t002" ref-type="table">Table 2</xref>). The EPT&#x02014;<italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS binding has a higher enthalpic contribution (1.1 to 3.2 kcal mol<sup>-1</sup>), while the EPT&#x02014;<italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS binding has a lower entropic contribution (5.5 to 3.3 kcal mol<sup>-1</sup>).</p><table-wrap position="float" id="ppat.1009965.t002"><object-id pub-id-type="doi">10.1371/journal.ppat.1009965.t002</object-id><label>Table 2</label><caption><title>Thermodynamic analysis of EPT binding with LeuRS.</title></caption><alternatives><graphic xlink:href="ppat.1009965.t002" id="ppat.1009965.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">Bacteria</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x00394;G (kcal mol<sup>-1</sup>)</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">&#x00394;H (kcal mol<sup>-1</sup>)</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">-T&#x00394;S (kcal mol<sup>-1</sup>)</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">Kd (&#x003bc;M)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic></td><td align="left" rowspan="1" colspan="1">-6.49 &#x000b1; 0.07</td><td align="left" rowspan="1" colspan="1">-3.2 &#x000b1; 0.4</td><td align="left" rowspan="1" colspan="1">-3.3 &#x000b1; 0.3</td><td align="left" rowspan="1" colspan="1">16 &#x000b1; 4</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic></td><td align="left" rowspan="1" colspan="1">-6.9 &#x000b1; 0.2</td><td align="left" rowspan="1" colspan="1">-1.1 &#x000b1; 0.3</td><td align="left" rowspan="1" colspan="1">-5.5 &#x000b1; 0.5</td><td align="left" rowspan="1" colspan="1">10 &#x000b1; 4</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>&#x00394;G, change in Gibbs free energy; &#x00394;H, change in enthalpy; &#x00394;S, change in entropy; T, temperature (303K)</p></fn><fn id="t002fn002"><p>Kd, dissociation constant</p></fn></table-wrap-foot></table-wrap><p>To gain insight into the interactions between EPT and LeuRS, we solved the crystal structure of the <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> editing domain (LeuRS<sub>303-498</sub>). We obtained the crystal structures of the LeuRS editing domain unliganded 2.1 &#x000c5; resolution (PDB 7N11) and in complex with the adenosine monophosphate (AMP) adduct with EPT at 1.7 &#x000c5; resolution (PDB 7N12, <xref rid="ppat.1009965.s012" ref-type="supplementary-material">S7 Table</xref>). AMP acts as a surrogate for the 3&#x02019; end of the tRNA acceptor stem. In concordance with the binding mode of action of benzoxaboroles [<xref rid="ppat.1009965.ref019" ref-type="bibr">19</xref>], we detected strong electron density in the active site corresponding to the EPT-AMP adduct formed through covalent interactions between the boron atom of EPT and the 2&#x02019; and 3&#x02019; hydroxyl groups on the ribose ring of AMP (Figs <xref rid="ppat.1009965.g004" ref-type="fig">4A</xref> and <xref rid="ppat.1009965.s005" ref-type="supplementary-material">S5A</xref>). Comparing unliganded and liganded residues in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> editing domain structures shows a sizable shift of residues 416&#x02013;422, located around the adenosine pocket, upon drug binding, including ordering of Y421 to interact with the EPT-AMP adduct phosphate, and a decrease of B factors in the neighbouring residues (<xref rid="ppat.1009965.s005" ref-type="supplementary-material">S5B Fig</xref>). This increase in order could explain the relatively lower entropic contribution to binding observed in ITC, although an unliganded <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> structure is not available for comparison.</p><fig position="float" id="ppat.1009965.g004"><object-id pub-id-type="doi">10.1371/journal.ppat.1009965.g004</object-id><label>Fig 4</label><caption><title>Similar binding of benzoxaboroles to the editing domain of LeuRS.</title><p>EPT-AMP (blue) bound in the active site of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS (cyan) and a similar benzoxaborole-AMP (brown) bound in active site of <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> LeuRS (PDB 5AGR) (orange). <bold>A</bold> Critical arginine and aspartic acid residues make similar interactions with benzoxaboroles. <bold>B</bold> Phosphate from AMP pivots towards threonine residue in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS. Conformer 1 of T323 points OH towards EPT, while conformer 2 orients OH towards the phosphate.</p></caption><graphic xlink:href="ppat.1009965.g004" position="float"/></fig><p>Once bound with benzoxaborole-AMP adduct, the active sites of <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> (PDB: 5AGR) [<xref rid="ppat.1009965.ref019" ref-type="bibr">19</xref>] and <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS, and mode of adduct binding are very similar (Figs <xref rid="ppat.1009965.g004" ref-type="fig">4A</xref> and <xref rid="ppat.1009965.s005" ref-type="supplementary-material">S5C</xref>). Both proteins make critical contacts with the primary amine side chain through D433 (D447 in <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic>) and the universally conserved D436 (D450 in <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic>) (<xref rid="ppat.1009965.g004" ref-type="fig">Fig 4A</xref>). In addition, R435 (R449 in <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic>) hydrogen bonds with the ethoxy oxygen of EPT and packed with the ribose of AMP (<xref rid="ppat.1009965.g004" ref-type="fig">Fig 4A</xref>). The packing interaction on the ribose of AMP is underscored from <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> mutants with R435H variants that lead to resistance early in the phase 2 clinical trial for complicated urinary tract infections. EPT has a hydroxypropyl ether moiety, rather than the ethyl ether in the benzoxaborole bound to <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> LeuRS, but the extension shows very weak electron density and likely does not contribute to binding. The only notable difference is a ~1 &#x000c5; shift in phosphate group of the EPT-AMP adduct (<xref rid="ppat.1009965.g004" ref-type="fig">Fig 4B</xref>). In both complexes, the phosphate is pinned between Y421 (Y435) and T323 (T337). The electron density indicates that there are multiple rotomeric conformations of T323, meaning its hydroxyl could hydrogen bond with the phosphate or with the 3&#x02019; O and ether oxygen of the adduct (<xref rid="ppat.1009965.g004" ref-type="fig">Fig 4B</xref>). <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> LeuRS T337 is modelled in the latter position, but inspection of deposited maps also indicates multiple rotomeric conformations. Variants at T322, T323 and T327 were identified in <italic toggle="yes">P</italic>. <italic toggle="yes">aeruginosa</italic> and <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> mutants resistant to benzoxaboroles, which supports the importance of the threonine rich region for editing activity [<xref rid="ppat.1009965.ref032" ref-type="bibr">32</xref>]. From the structural data, we propose that EPT binds LeuRS from <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> and <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> in a similar manner with similar affinity, providing a shared pathway for future structure-activity relationship analysis.</p></sec><sec id="sec008"><title>Norvaline is toxic to editing-deficient EPT mutants</title><p>Since resistance to EPT was shown in a phase 2 clinical trial of complicated urinary tract infections from <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic>, we sought a way to minimize the emergence of resistance in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> pulmonary infections [<xref rid="ppat.1009965.ref030" ref-type="bibr">30</xref>]. We hypothesized that norvaline, a non-proteinogenic amino acid absent from extant proteins [<xref rid="ppat.1009965.ref033" ref-type="bibr">33</xref>], would be toxic to <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> editing-deficient mutants that acquired EPT resistance. When challenged with 59 &#x003bc;g/mL norvaline, the D436H editing-deficient mutant was significantly reduced in growth, while the wild-type strain was not inhibited (<xref rid="ppat.1009965.g005" ref-type="fig">Fig 5A</xref>). The mutant strain complemented with wild-type <italic toggle="yes">leuS</italic> (D436H::leuS<sup>D</sup>) displayed a two-day lag before significant growth. As controls, leucine and isoleucine were not toxic to the D436H mutant. There was however a minor reduction in mutant growth in 59 &#x003bc;g/mL valine, but no growth difference between the D436H and D436H::leuS<sup>D</sup> strains. Thus, we cannot conclude that valine exerts some toxicity to editing-deficient strains. Next, we asked if norvaline toxicity could be rescued with branched-chain amino acids (BCAAs). The D436H mutant was grown in 59 &#x003bc;g/mL norvaline with varying concentrations of BCAAs. Leucine but not isoleucine or valine rescued growth (<xref rid="ppat.1009965.g005" ref-type="fig">Fig 5B</xref>). These observations corroborate the results that LeuRSs contain natural selectivity with their aminoacylation site for leucine and can discriminate against isoleucine and valine, but to a lesser extent against norvaline as non-cognate amino acids [<xref rid="ppat.1009965.ref034" ref-type="bibr">34</xref>].</p><fig position="float" id="ppat.1009965.g005"><object-id pub-id-type="doi">10.1371/journal.ppat.1009965.g005</object-id><label>Fig 5</label><caption><title>Norvaline is toxic to <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> D436H editing deficient mutants.</title><p><bold>A</bold> ATCC 19977, D436H mutant, and D436H:leuS<sup>D</sup> complement strains were grown in Sauton media with 59 &#x003bc;g/mL norvaline (top left), 66 &#x003bc;g/mL leucine (top right), 59 &#x003bc;g/mL valine (lower left), or 66 &#x003bc;g/mL isoleucine (lower right). Data shown is from three biological replicates, one-way ANOVA with Tukey&#x02019;s multiple comparisons test. ****, p &#x0003c; 0.0001. <bold>B</bold> D436H mutant grown in Sauton media with 59 &#x003bc;g/mL norvaline and a range of leucine (left), isoleucine (middle), or valine (right). D436H mutant grown in 0 &#x003bc;g/mL norvaline and 0 &#x003bc;g/mL BCAA represents growth control. D436H mutant grown in 59 &#x003bc;g/mL norvaline and 0 &#x003bc;g/mL BCAA represents inhibited growth control. BCAAs added to cultures from 33 &#x003bc;g/mL to 262 &#x003bc;g/mL (Leu/Ile) or 29 &#x003bc;g/mL to 234 &#x003bc;g/mL (Val). Data shown is mean &#x000b1; SD from three biological replicates. Groups compared to inhibited growth control with one-way ANOVA with Dunnett&#x02019;s multiple comparisons test. ***, p = 0.0009; ****, p &#x02264; 0.0001.</p></caption><graphic xlink:href="ppat.1009965.g005" position="float"/></fig></sec><sec id="sec009"><title>Norvalination of the proteome induces the heat shock response</title><p>To provide a mechanism of norvaline toxicity, we analyzed the proteomes of wild-type, D436H mutant, and D436H:leuS<sup>D</sup> grown in norvaline or valine as control. We analyzed ~2500 proteins from whole-cell lysates after 12 hours or 3 days of incubation in 59 &#x003bc;g/mL norvaline or valine using reverse-phase HPLC/MS. Proteins filtered for leucine residues 14 Da lighter (14 Da corresponds to missing methylene group on norvaline) were enumerated using spectral counting. The wild-type maintained preferential incorporation of leucine into proteins, while the D436H mutant had a median norvaline misincorporation in 6% of the proteome after 12 hours. However, the amount of norvaline misincorporation between the D436H mutant and the D436H::leuS<sup>D</sup> strain was not significantly different (<xref rid="ppat.1009965.g006" ref-type="fig">Fig 6A</xref>). Given that there was a two-day delay when the complemented strain was grown in norvaline (<xref rid="ppat.1009965.g005" ref-type="fig">Fig 5A</xref>), we hypothesized that the effects of gene complementation would be seen at a later time point when grown in 59 &#x003bc;g/mL norvaline. The experiments were repeated, and the strains were incubated for 3 days. Again, the median norvalination increased in the D436H mutant relative to wild-type, but the level of misincorporated norvaline increased to 20% of the proteome. At this time point, the complemented strain partially rescued the level of norvalination after 3 days (<xref rid="ppat.1009965.g006" ref-type="fig">Fig 6B</xref>). In all conditions tested, we measured background misaminoacylation of valine in the proteome (<xref rid="ppat.1009965.g006" ref-type="fig">Fig 6A and 6B</xref>).</p><fig position="float" id="ppat.1009965.g006"><object-id pub-id-type="doi">10.1371/journal.ppat.1009965.g006</object-id><label>Fig 6</label><caption><title>Norvaline misaminoacylation in editing deficient mutants alters the proteomic landscape.</title><p><bold>A-B</bold>
<italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977 or D436H mutant was grown in 59 &#x003bc;g/mL valine or 59 &#x003bc;g/mL norvaline for 12 hours or 3 days. Valine was used as a specificity control. Total cell lysate was collected. (Nor)valinated protein medians from the proteomes were compared using Kruskal-Wallis with Dunn&#x02019;s multiple comparisons test. ***, p = 0.0005; ****, p &#x0003c; 0.0001; ns, no statistical significance. <bold>C-F</bold> Protein fold abundance shown as D436H mutant relative to <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977. Dashed red lines indicate 0.5x and 2x fold abundance thresholds for biologically relevant changes.</p></caption><graphic xlink:href="ppat.1009965.g006" position="float"/></fig><p>Next, we asked how the cell responded to stress caused by norvaline misincorporation in the proteome. Using total spectral counting, we determined the fold change in protein abundance from D436H mutant relative to wild-type. There was a distinct increase in proteins when challenged with norvaline that was absent from the valine control (<xref rid="ppat.1009965.g006" ref-type="fig">Fig 6C-F</xref>). We used the protein-protein interaction (PPI) mapping tool STRING to identify upregulated proteins with common functions. When 130 of the most highly abundant proteins after norvaline stress were mapped for PPIs (<xref rid="ppat.1009965.g007" ref-type="fig">Fig 7A</xref>), proteins belonging to the Clp protease family (ClpP1, ClpP2, ClpX) and GroEL chaperonin family (GroEL, GroL2, GroS) were identified (False discovery rate 7.2x10<sup>-4</sup> at 12 h, 2.1x10<sup>-5</sup> at 3 d) (<xref rid="ppat.1009965.g007" ref-type="fig">Fig 7C</xref>). As a control, 130 randomly selected proteins from the norvaline dataset were not enriched for chaperonins and proteases when analyzed for PPIs (<xref rid="ppat.1009965.g007" ref-type="fig">Fig 7B</xref>). We also observed a temporal change in chaperonin and protease levels where early stress from norvaline at 12 hours upregulated chaperonins followed by protease upregulation at 3 days (<xref rid="ppat.1009965.g007" ref-type="fig">Fig 7D</xref>). This data suggests that norvaline misincorporation into the proteome results in toxicity from misfolded proteins [<xref rid="ppat.1009965.ref014" ref-type="bibr">14</xref>,<xref rid="ppat.1009965.ref033" ref-type="bibr">33</xref>,<xref rid="ppat.1009965.ref035" ref-type="bibr">35</xref>&#x02013;<xref rid="ppat.1009965.ref040" ref-type="bibr">40</xref>].</p><fig position="float" id="ppat.1009965.g007"><object-id pub-id-type="doi">10.1371/journal.ppat.1009965.g007</object-id><label>Fig 7</label><caption><title>Norvaline stress induces the heat shock response in editing deficient mutants.</title><p><bold>A</bold> Protein-protein interaction network from the 130 most abundant proteins in D436H mutant when challenged with 59 &#x003bc;g/mL norvaline for 12 hours. 942 PPIs identified with PPI enrichment p-value &#x0003c; 1.0x10<sup>-16</sup>. <bold>B</bold> PPI network from 130 randomly selected proteins in D436H mutant when challenged with 59 &#x003bc;g/mL norvaline for 12 hours. 102 PPIs identified with PPI enrichment p-value of 0.0397. <bold>C</bold> Clp protease/chaperonin family local network cluster identified in <bold>a</bold> (false discovery rate: 0.00072). <bold>D</bold> Temporal signature of the heat shock response. Protein expression levels of D436H norvaline relative to WT norvaline were measured by spectral counting.</p></caption><graphic xlink:href="ppat.1009965.g007" position="float"/></fig></sec><sec id="sec010"><title>Norvaline reduces resistance to EPT <italic toggle="yes">in vitro</italic> and potentiates EPT activity <italic toggle="yes">in vivo</italic></title><p>Knowing that norvaline targets LeuRS editing domain, we asked if norvaline could prevent escape mutants to EPT <italic toggle="yes">in vitro</italic>. We observed a 23-fold reduction in escape mutant frequency when <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977 was plated on 7H10 plates containing 10X MIC<sub>90</sub> EPT and 590 &#x003bc;g/mL norvaline (1.89 x 10<sup>&#x02212;10</sup>) over EPT alone (4.28 x 10<sup>&#x02212;9</sup>) (<xref rid="ppat.1009965.g008" ref-type="fig">Fig 8A</xref>); as a control, RFB did not benefit from norvaline supplementation. To test whether this effect would be observed in other mycobacteria, we repeated with <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic>, again observing a suppression of EPT mutants with norvaline exposure (<xref rid="ppat.1009965.g008" ref-type="fig">Fig 8A</xref>). Next, the MIC<sub>90</sub> of EPT against <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977 was measured with differing doses of norvaline (<xref rid="ppat.1009965.g008" ref-type="fig">Fig 8B</xref>). Norvaline had no effect on the MIC<sub>90</sub> even up to 590 &#x003bc;g/mL. These results suggest norvaline does not act as a traditional adjuvant to EPT.</p><fig position="float" id="ppat.1009965.g008"><object-id pub-id-type="doi">10.1371/journal.ppat.1009965.g008</object-id><label>Fig 8</label><caption><title>Norvaline improves epetraborole efficacy <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>.</title><p><bold>A</bold> Mutant frequency to 10X MIC<sub>90</sub> EPT (0.63 &#x003bc;g/mL) or 10X MIC<sub>90</sub> EPT + 10X MIC<sub>90</sub> norvaline (590 &#x003bc;g/mL) in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977 and <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> H37Rv. Data shown is mean &#x000b1; SD from biological triplicates. Means compared using Poisson distribution. *, p &#x0003c; 0.0001; ns, no statistical significance. <bold>B</bold>
<italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> susceptibility to EPT with norvaline as an adjuvant. Data shown is mean &#x000b1; SD from one experiment representative of three. <bold>C</bold> EPT <italic toggle="yes">in vivo</italic> activity in SCID mouse model of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> lung infection with norvaline supplementation. Rifabutin (RFB) acts as positive control. Data shown is mean &#x000b1; SD of three to five mice per treatment group. Means compared using one-way ANOVA with Tukey&#x02019;s multiple comparisons test. **, p &#x0003c; 0.007; ***, p &#x0003c; 0.0005; ****; p &#x0003c; 0.0001; ns, no statistical significance.</p></caption><graphic xlink:href="ppat.1009965.g008" position="float"/></fig><p>We evaluated EPT and norvaline combination therapy for <italic toggle="yes">in vivo</italic> activity in a NOD.SCID mouse model of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infection [<xref rid="ppat.1009965.ref041" ref-type="bibr">41</xref>]. Mice were infected intranasally with a high inoculum of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> (~10<sup>6</sup> CFU). Treatment was started 1-day post-infection with once-daily oral vehicle (carboxymethylcellulose), RFB as positive control (10 mg/kg), EPT (10 mg/kg), EPT + norvaline (10 mg/kg + 3.3 mg/kg), or norvaline (3.3 mg/kg). Norvaline was dosed at 3.3 mg/kg (5 mM) which represents ~10X MIC<sub>90</sub>
<italic toggle="yes">in vitro</italic> against the editing deficient D436H mutant. Previously, norvaline had been shown to be an effective <italic toggle="yes">in vivo</italic> neuroprotective agent as an arginase inhibitor at 2 mM in a triple-transgenic mouse model of Alzheimer&#x02019;s disease [<xref rid="ppat.1009965.ref042" ref-type="bibr">42</xref>]. Compared to vehicle-treated mice, we measured a 1 log<sub>10</sub> decrease in bacterial burden in the lungs from RFB or EPT treatment. Furthermore, the addition of norvaline to the EPT group was significantly more active than EPT alone with an additional ~1 log<sub>10</sub> decrease in bacterial burden in the lungs while norvaline alone had no significant effect (<xref rid="ppat.1009965.g008" ref-type="fig">Fig 8C</xref>).</p></sec></sec><sec sec-type="conclusions" id="sec011"><title>Discussion</title><p>Our data and two recent publications [<xref rid="ppat.1009965.ref043" ref-type="bibr">43</xref>,<xref rid="ppat.1009965.ref044" ref-type="bibr">44</xref>] confirmed the activity of benzoxaboroles against mycobacteria using zebrafish and murine models of infection and we showed that benzoxaboroles can be potentiated when combined with norvaline. Specifically, we demonstrated that the combination of EPT with norvaline reduces the emergence of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> and <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> mutants and results in increased activity <italic toggle="yes">in vivo</italic> compared to EPT. Whether norvaline can be a therapeutic adjunct for other benzoxaboroles remains to be established, but is supported by observations with tavaborole and norvaline in <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> [<xref rid="ppat.1009965.ref045" ref-type="bibr">45</xref>]. The potential for combination therapy may be of value in non-mycobacterial applications, such as the treatment of urinary tract infections, where EPT did not progress beyond phase 2 studies owing to the rapid emergence of resistance [<xref rid="ppat.1009965.ref030" ref-type="bibr">30</xref>].</p><p>While we documented that EPT is active against both <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> and <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis in vitro</italic>, unexpectedly, we observed that EPT is more active against <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>, which conflicts with the standard experience in antimycobacterial drug discovery [<xref rid="ppat.1009965.ref006" ref-type="bibr">6</xref>,<xref rid="ppat.1009965.ref046" ref-type="bibr">46</xref>&#x02013;<xref rid="ppat.1009965.ref051" ref-type="bibr">51</xref>]. Our cocrystal structure and ITC data point to similarities and differences in the interaction of EPT with the respective LeuRS proteins. Most notably, while the Kd values were similar, the enthalpy was greater for the EPT interaction with LeuRS of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>. Knowing that compounds with more enthalpically favourable binding are prioritized in hit-to-lead optimization [<xref rid="ppat.1009965.ref052" ref-type="bibr">52</xref>], it may be possible that the discordance in enthalpy in part explains the difference in biological activity of EPT against the two organisms (MIC<sub>90Mabs</sub> 0.063 &#x003bc;g/mL vs MIC<sub>90Mtb</sub> 0.46 &#x003bc;g/mL). Other possibilities explaining the difference in whole-cell activity may be linked to differential expression level of <italic toggle="yes">leuS</italic> in both species, the lack of efflux pumps in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>, or the inability of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> to survive conditions that mimic leucine starvation, although these remain to be addressed. At a minimum, the current data can be used for future structure-activity relationship studies aimed at uncovering analogues with improved potency against LeuRS of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>, <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> and other mycobacteria.</p><p>Our <italic toggle="yes">in vivo</italic> data shows the value of EPT alone in rescuing zebrafish embryos from lethal <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infection and that EPT + norvaline can control experimental pulmonary <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infection to a greater degree than the control antibiotic, RFB. Rather than acting as a traditional adjuvant like <italic toggle="yes">&#x003b2;</italic>-lactamase inhibitors for <italic toggle="yes">&#x003b2;</italic>-lactams [<xref rid="ppat.1009965.ref053" ref-type="bibr">53</xref>], we propose that norvaline potentiates EPT <italic toggle="yes">in vitro</italic> activity by maintaining a pharmacological pressure on <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> to remain editing proficient and limit the toxicity induced by the unfolded protein response and thus, limiting escape mutants. However, given that our <italic toggle="yes">in vivo</italic> model of pulmonary <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infection in NOD.SCID mice does not exceed a bacterial burden of ~10<sup>7</sup> in the lungs and that the rate of resistance against EPT is ~10<sup>&#x02212;9</sup>, other mechanisms might better explain our findings. Since the NOD.SCID model is immunocompromised for NK cells and adaptive immunity, macrophages&#x02014;the most notable front-line defence for mycobacterial pulmonary infections&#x02014;would be the main immune cell responsible for controlling the <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infection. One of the primary mechanisms of macrophages for controlling infections is the production of reactive nitrogen species like nitric oxide (NO) from inducible nitric oxide synthase (iNOS). Because NO is produced from arginine by iNOS, macrophages must regulate arginine metabolism between iNOS and the urea cycle, which naturally metabolizes arginine through the enzyme arginase. Interestingly, norvaline was shown to be an inhibitor of arginase and this resulted in increased production of NO in activated macrophages [<xref rid="ppat.1009965.ref054" ref-type="bibr">54</xref>,<xref rid="ppat.1009965.ref055" ref-type="bibr">55</xref>]. This increased production of NO from arginase inhibition might explain the lower bacterial burden observed in the NOD.SCID mouse group that received EPT + norvaline treatment.</p><p>Given that response rates to <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> treatment are poor, resulting in chronic and potentially untreatable pulmonary and dermatologic infections, we submit that benzoxaboroles with the addition of a leucine mimic hold promise for the treatment of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infections, and potentially other mycobacterial infections, such as tuberculosis.</p></sec><sec sec-type="materials|methods" id="sec012"><title>Materials and methods</title><sec id="sec013"><title>Ethics statement</title><p>All protocols involving mice followed the guidelines of the Canadian Council on Animal Care (CCAC) and were approved by the ethics committees of the RI-MUHC (project identifier [ID] 2015&#x02013;7656).</p></sec><sec id="sec014"><title>Culture conditions</title><p>Mycobacteria strains were grown in rolling liquid culture at 37&#x000b0;C in Middlebrook 7H9 (Difco) supplemented with 10% albumin dextrose catalase (ADC), 0.2% glycerol, and 0.05% Tween 80 (7H9 complete) or on 7H10 agar plates supplemented with 10% oleic acid ADC and 0.5% glycerol at 37&#x000b0;C. When mentioned, the carbon source was modified from glycerol to acetate or the detergent Tween 80 was removed from the media. <italic toggle="yes">Bacillus cereus</italic> (clinical isolate), <italic toggle="yes">Corynebacterium glutamicum</italic> (ATCC 13032), <italic toggle="yes">Escherichia coli</italic>, and <italic toggle="yes">Pseudomonas aeruginosa</italic> PAO1 were grown in LB broth. HepG2 cells (ATCC HB-8065) were grown in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM) with phenol red (from Gibco) supplemented with 10% fetal bovine serum at 37&#x000b0;C with 5% CO<sub>2</sub>.</p></sec><sec id="sec015"><title>Compound libraries</title><p>The GSK library contains 176 small molecules with antimycobacterial activity, specifically against <italic toggle="yes">Mycobacterium tuberculosis</italic> [<xref rid="ppat.1009965.ref056" ref-type="bibr">56</xref>]. Medicines for Malaria Venture created two compound sets: the Pathogen Box and the Pandemic Response Box. The Pathogen Box is composed of 400 molecules active against various disease sets (<ext-link xlink:href="https://www.mmv.org/mmv-open/pathogen-box/about-pathogen-box" ext-link-type="uri">https://www.mmv.org/mmv-open/pathogen-box/about-pathogen-box</ext-link>). The Pandemic Response Box is composed of 400 diverse drug-like molecules broadly categorized as antibacterials (201 molecules), antivirals (153 molecules), and antifungals (46 molecules) (<ext-link xlink:href="https://www.mmv.org/mmv-open/pandemic-response-box/about-pandemic-response-box" ext-link-type="uri">https://www.mmv.org/mmv-open/pandemic-response-box/about-pandemic-response-box</ext-link>).</p></sec><sec id="sec016"><title>Library screening</title><p>MMV Pathogen Box, MMV Pandemic Response Box, and GSK TB-active libraries were screened against <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977 strain which constitutively expressed the <italic toggle="yes">luxCDABE</italic> operon (<italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> lux) at 10 &#x003bc;M in duplicate in 96-well flat-bottom plates in 7H9 complete media. The culture was grown to log phase (OD<sub>600</sub> 0.4&#x02013;0.8) and diluted to OD<sub>600</sub> 0.005 (5x10<sup>6</sup> CFU/mL). 90 &#x003bc;L of culture was mixed with 10&#x003bc;L of compound. Plates were sealed with parafilm and incubated at 37&#x000b0;C for 48 hours. Plates had a column of 0.1% DMSO as negative controls (drug-free conditions) and 64 &#x003bc;g/mL of AMK as positive controls. Luminescence was measured with an Infinite F200 Tecan plate reader. % Luminescence relative to DMSO control was plotted using GraphPad Prism version 9. Compounds that decreased luminescence &#x02264; 10% were classified as primary hits. Primary hits were screened against <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977 at 10 &#x003bc;M in triplicate using REMA (see &#x0201c;Determination of MIC&#x0201d; below). Plates were setup as performed for the primary screen. Fluorescence was measured with an Infinite F200 Tecan plate reader. % bacteria viability relative to DMSO control was plotted using GraphPad Prism version 9. Compounds that decreased bacteria viability &#x02264; 10% were classified as confirmed hits. Confirmed hits were followed up with dose-response curves to determine the minimum inhibitory concentration (MIC).</p></sec><sec id="sec017"><title>Determination of minimum inhibitory concentrations (MIC)</title><p>MIC values were determined using the resazurin microtiter assay (REMA). Cultures were grown to log phase (OD<sub>600</sub> of 0.4&#x02013;0.8) and diluted to OD<sub>600</sub> of 0.005. Drugs were prepared in two-fold serial dilutions in 96-well plates with 90 &#x003bc;L of bacteria per well to a final volume of 100 &#x003bc;L. Plates were incubated at 37&#x000b0;C until drug-free wells were turbid (2 days for <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>). Ten &#x003bc;L of resazurin (0.025% wt/vol) was added to each well. Once the drug-free wells turned pink (one doubling time), the fluorescence (ex/em 560nm/590nm) was measured using an Infinite F200 Tecan plate reader. Fluorescence intensities were converted to % viable cells relative to drug-free conditions and fit to the Gompertz equation using GraphPad Prism version 9. MIC values at 90% growth inhibition were determined from the nonlinear regression Gompertz equation.</p></sec><sec id="sec018"><title>In vitro cytotoxicity in HepG2 cells</title><p>Drugs were prepared in two-fold serial dilutions in 96-well plates with 45 &#x003bc;L of Human HepG2 cells (2,000 cells/well) to a final volume of 50 &#x003bc;L. Plates were incubated for 3 days at 37&#x000b0;C with 5% CO<sub>2</sub>. Five &#x003bc;L of resazurin (0.025% wt/vol) was added to each well and incubated for 4 hours at 37&#x000b0;C. Cell viability was determined from the fluorescence intensity as done in the previous REMA assay. 50% toxic dose concentrations (TD<sub>50</sub>) values were obtained using a nonlinear regression fit equation ([inhibitor] vs response, variable slope) in GraphPad Prism version 9.</p></sec><sec id="sec019"><title>Assessment of EPT efficacy in infected Zebrafish</title><p>Experiments in zebrafish were conducted according to the Comit&#x000e9; d&#x02019;Ethique pour l&#x02019;Exp&#x000e9;rimentation Animale de la R&#x000e9;gion Languedoc Roussillon under reference 2020022815234677V3. Experiments were performed using the <italic toggle="yes">golden</italic> mutant and macrophage reporter Tg(<italic toggle="yes">mpeg1</italic>:<italic toggle="yes">mCherry)</italic> lines as previously described [<xref rid="ppat.1009965.ref057" ref-type="bibr">57</xref>]. Embryos were obtained and maintained as described [<xref rid="ppat.1009965.ref027" ref-type="bibr">27</xref>]. Embryo age is expressed as hours post fertilisation (hpf). Green fluorescent <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> CIP104536<sup>T</sup> (R) expressing Wasabi were prepared and microinjected in the caudal vein (2&#x02013;3 nL containing &#x02248;100 bacteria/nL) in 30 hpf embryos previously dechorionated and anesthetized with tricaine [<xref rid="ppat.1009965.ref058" ref-type="bibr">58</xref>]. The bacterial inoculum was checked <italic toggle="yes">a posteriori</italic> by injection of 2 nL in sterile PBS<sup>T</sup> and plating on 7H10<sup>OADC</sup>. Infected embryos were transferred into 6-well plates (12 embryos/well) and incubated at 28.5&#x000b0;C to monitor kinetics of infection and embryo survival. Survival curves were determined by counting dead larvae daily for up to 11 days, with the experiment concluded when uninfected embryos started to die. EPT treatment of infected embryos and uninfected embryos was commenced at 24 hpi (hours post-infection) for 5 days. The drug-containing solution was renewed daily. Bacterial loads in live embryos were determined by anesthetising embryos in tricaine as previously described [<xref rid="ppat.1009965.ref059" ref-type="bibr">59</xref>], mounting on 3% (w/v) methylcellulose solution and taking fluorescent images using a Zeiss Axio Zoom.V16 coupled with an Axiocam 503 mono (Zeiss). Fluorescence Pixel Count (FPC) measurements were determined using the &#x02018;Analyse particles&#x02019; function in ImageJ [<xref rid="ppat.1009965.ref058" ref-type="bibr">58</xref>]. All experiments were completed at least three times independently.</p></sec><sec id="sec020"><title>Isolation of resistant mutants</title><p>Early log phase <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> (OD<sub>600</sub> 0.1&#x02013;0.4) was cultured and resuspended to an OD<sub>600</sub> of 10. Ten mL of culture was kept as a reference strain for future sequencing. One hundred &#x003bc;L of OD<sub>600</sub> 10 (approx. 1 X 10<sup>9</sup> CFU/100&#x003bc;L) was plated on solid media containing 10X, 20X, or 40X MIC<sub>90</sub> of the compound of interest. AMK was used as a control antibiotic. Plates were incubated for 5 days at 37&#x000b0;C. Number of colonies were counted to obtain mutation frequencies. Resistant colonies were transferred into fresh media without antibiotics (to avoid the emergence of secondary mutations). The MIC (REMA method) was measured for the mutant against the compound of interest as well as a panel of reference compounds with different targets for negative controls.</p></sec><sec id="sec021"><title>Sequencing resistant mutants</title><p>Genomic DNA (gDNA) was extracted from the 10 mL reference aliquot of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> harvested during mutant isolation and fresh cultures of mutant strains with confirmed resistance (REMA method) using the Qiagen QIAamp UCP Pathogen Mini kit with a modified mechanical lysis protocol. Pellet culture by centrifugation and resuspend in 590 &#x003bc;L of ATL buffer containing the Dx reagent in a low-bind tube. Add 40 &#x003bc;L of proteinase K (20 mg/mL) and 20 &#x003bc;L of lysozyme (100 mg/mL) and incubate for 30 minutes at 56&#x000b0;C under agitation. Transfer into a Pathogen Lysis Tube L and vortex twice using a FastPrep-24 instrument at 6.5 m/s for 45 s with a 5-minute incubation on ice in between. Transfer supernatant into fresh 2 mL low-bind tube. Follow manufacturer&#x02019;s instructions for sample prep with spin protocol. gDNA was quantified with Quant-iT PicoGreen dsDNA kit. <italic toggle="yes">leuS</italic> from ATCC 19977 and EPT mutants was sequenced with Sanger Sequencing with the primers listed in <xref rid="ppat.1009965.s010" ref-type="supplementary-material">S5 Table</xref>.</p></sec><sec id="sec022"><title>Cloning and over-expressing mutant <italic toggle="yes">leuS</italic> in <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic></title><p>Wildtype and mutant <italic toggle="yes">leuS</italic> (D436H) were PCR amplified from gDNA using Phusion with primers 1 &#x00026; 2 (see <xref rid="ppat.1009965.s010" ref-type="supplementary-material">S5 Table</xref>), ligated into pMV306_hsp60 digested with EcoRV and HindIII restriction enzymes, and transformed into <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> DH5<italic toggle="yes">&#x003b1;</italic> cells (Promega). Plasmids were extracted and sequenced with primers 3&#x02013;12 (see <xref rid="ppat.1009965.s010" ref-type="supplementary-material">S5 Table</xref>) using Sanger sequencing.</p></sec><sec id="sec023"><title>Protein purification</title><p>The <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS editing domain (residues 303&#x02013;499 of WP005112800.1) and the <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> LeuRS editing domain (residues 311&#x02013;512 of WP_003900794.1) were synthesized with an N-terminal polyhistidine tag and tobacco etch virus (TEV) protease recognition site, with codon optimization for <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> and cloned into pET24a(+) by the company BioBasic to create pMabsED and pMtbED, respectively. <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> BL21 (DE3) cells were transformed with pMabsED or pMtbED and grown overnight at 37&#x000b0;C on LB-agar with 50 &#x003bc;g/mL kanamycin. Single colonies were transferred into 100 mL of LB media with 50 &#x003bc;g/mL kanamycin (LB-kan) and grown overnight at 37&#x000b0;C. One liter of LB-kan was inoculated with 10 mL of the overnight culture and grown at 37&#x000b0;C until an optical density at 600 nm of 0.6 was reached. Protein expression was then induced with addition of 0.5 mM IPTG and the culture further incubated for 18 h at 16&#x000b0;C. The cells were harvested by centrifugation (4000 g for 20 min), resuspended in buffer A (50 mM Tris, 150 mM NaCl, 2 mM BME) plus 2 mM PMSF, lysed using sonication (55% amplitude, 30 cycles of 10s on 20s off) and the lysate clarified by ultracentrifugation (40,000 g for 30 min). The lysate was loaded onto a HiTrap FF (Cytiva) and eluted with buffer A plus 500 mM imidazole. The eluate was dialyzed in buffer A, digested with TEV protease overnight and the protease as well as non-cleaved protein separated from cleaved protein by application to the HiTrap FF column with flow-through collected. Protein was then subjected to size exclusion chromatography using a HiLoad Superdex Increase 75 colum (Cytiva), with fractions containing pure protein pooled.</p></sec><sec id="sec024"><title>Isothermal titration calorimetry</title><p>ITC measurements were performed at 30&#x000b0;C on a VP-ITC system (Malvern Panalytical Inc). Epetraborole (100 &#x003bc;M) in measurement buffer (50 mM Tris, 150 mM NaCl, 2 mM BME, 10 mM AMP) was titrated with protein solution (1 mM) in measurement buffer over 29 injections of 10 &#x003bc;l with 300 seconds equilibration time between injections. The heat evolved after each protein injection was calculated by integrating the calorimetric signal. The binding isotherms obtained were fitted to a single-site model using Origin 7 (Microcal Inc.). Experiments were performed in triplicates.</p></sec><sec id="sec025"><title>Crystallography</title><p>Initial crystals of the <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS editing domain were obtained from sparse matrix screening in 96-well sitting drop format using a sample of 10 mg/mL protein in buffer A, and a precipitant solution of 100 mM HEPES pH 7.0 and 2 M ammonium sulfate, at room temperature. Diffraction-quality crystals were grown by mixing 2 &#x003bc;L of protein solution (7.5 mg/mL) and 2 &#x003bc;L of reservoir solution (100 mM HEPES pH 7.0 and 2.5 M ammonium sulfate) in 24-well sitting-drop format. Crystals were cryoprotected in 100 mM HEPES pH 7.0 and 3.5 M ammonium sulfate, looped and flash-vitrified in liquid nitrogen. Diffracting co-crystals of the editing domain and epetraborole were obtained by streak seeding un-liganded crystals shards into drops in 24-well sitting-drop format with a reservoir solution of 100 mM HEPES, pH 7.5, 2% PEG400, 2.1 M ammonium sulfate, 10 mM AMP, 1 mM epetraborole and 15% glycerol at room temperature. These crystals were directly looped and flash-vitrified in liquid nitrogen for diffraction experiments.</p></sec><sec id="sec026"><title>Structure determination</title><p>Diffraction data for the unliganded editing domain was collected at the Advanced Photon Source (24-ID-E) and data for the epetraborole&#x02013;editing domain complex at the Canadian Light Source (CMCF-08B1-1). The data sets were indexed, processed, and scaled with HKL2000 [<xref rid="ppat.1009965.ref060" ref-type="bibr">60</xref>] (for the unliganded editing domain) or DIALS [<xref rid="ppat.1009965.ref061" ref-type="bibr">61</xref>] (for the complex). Initial phases for the <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS editing domain were obtained using molecular replacement with the program Phaser [<xref rid="ppat.1009965.ref062" ref-type="bibr">62</xref>] using 5AGR [<xref rid="ppat.1009965.ref019" ref-type="bibr">19</xref>] as a search model. Iterative rounds of refinement with Phenix [<xref rid="ppat.1009965.ref063" ref-type="bibr">63</xref>] and manual modeling in Coot [<xref rid="ppat.1009965.ref064" ref-type="bibr">64</xref>] yielded the final unliganded structure. The structure of the <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS editing domain with epetraborole bound in the active site crystallized in a different crystal form (<xref rid="ppat.1009965.s010" ref-type="supplementary-material">S5 Table</xref>). Therefore, initial phases for the co-complex structure were obtained with molecular replacement using the program Phaser [<xref rid="ppat.1009965.ref062" ref-type="bibr">62</xref>] utilizing the unliganded structure as a search model. The model for epetraborole was generated with eLBOW [<xref rid="ppat.1009965.ref065" ref-type="bibr">65</xref>] and geometrical restraints were obtained with AceDRG [<xref rid="ppat.1009965.ref066" ref-type="bibr">66</xref>]. Iterative rounds of refinement using Phenix [<xref rid="ppat.1009965.ref063" ref-type="bibr">63</xref>] and manual modeling in Coot [<xref rid="ppat.1009965.ref064" ref-type="bibr">64</xref>] yielded the final co-complex structure.</p></sec><sec id="sec027"><title>Time-kill assays</title><p>Log phase (OD<sub>600</sub> of 0.4&#x02013;0.8) <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> was diluted to an OD<sub>600</sub> of 0.0001 (10<sup>5</sup> CFU/mL) and incubated with drugs of interest. One hundred &#x003bc;L aliquots were taken and serially diluted in 7H9 complete and plated on 7H10 agar. The starting inoculum was determined from time 0 before drugs were added. CFUs were determined after 4 days of incubation at 37&#x000b0;C. Bactericidal activity is defined as a 3 log<sub>10</sub> decrease (99.9%) from the starting inoculum.</p></sec><sec id="sec028"><title>Checkerboard assays</title><p>Drug combinations were assessed for synergy, indifference, or antagonism using the standard checkerboard format followed by REMA for MIC determination. Fractional inhibitory concentrations (FICs): FIC (X+Y) = (MIC of X in combination with Y)/(MIC of X alone). The fractional inhibitory concentration index (FICI) was calculated from FIC<sub>X</sub> + FIC<sub>Y</sub>. FICI values &#x0003c; 0.5 are defined as synergy, FICI values &#x02265; 4.0 are defined as antagonism, and FICI values in between are defined as indifferent. EPT was serially diluted two-fold from 4X MIC to 1/16 X MIC. Mycobacterial drugs were serially diluted two-fold from 8X MIC to 1/32X MIC.</p></sec><sec id="sec029"><title>Inducible resistance assay</title><p>To test whether <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> has inducible resistance to EPT, we performed a preexposure assay. Briefly, log phase <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> was diluted to 0.05 and grown overnight with &#x000bc; X MIC<sub>50</sub> of EPT (0.016 &#x003bc;g/mL) and CLR (0.016 &#x003bc;g/mL). After overnight growth, MICs were determined via REMA. Data is reported as the ratio of pre-exposed culture MIC to MIC of culture grown in drug-free conditions.</p></sec><sec id="sec030"><title>CRISPRi conditional knockdown of <italic toggle="yes">leuS</italic></title><p>The PLJR962 plasmid was restriction digested with BsmBI and gel purified. Synthetic oligo primers (<xref rid="ppat.1009965.s009" ref-type="supplementary-material">S4 Table</xref>) for the sgRNA with the PAM sequence for <italic toggle="yes">leuS</italic> were annealed and ligated into digested PLJR962 vector and transformed into <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> DH5<italic toggle="yes">&#x003b1;</italic>. Clones were sequenced using sequencing primer (<xref rid="ppat.1009965.s009" ref-type="supplementary-material">S4 Table</xref>). 500 ng of CRISPRi <italic toggle="yes">leuS</italic> vector was electroporated into <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977. Colonies were picked from 7H10 plates containing 250 &#x003bc;g/mL kanamycin and confirmed by PCR. <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> CRISPRi <italic toggle="yes">leuS</italic> was grown in liquid culture to early log phase (OD<sub>600</sub> 0.1&#x02013;0.4) and diluted to 1x10<sup>4</sup> CFU/mL. One hundred <italic toggle="yes">&#x003bc;</italic>L of culture was plated on 7H10 containing either serial dilutions of EPT or RFB as control, and 0, 0.05 &#x003bc;g/mL, or 0.1 &#x003bc;g/mL ATc, the inducer of the sgRNA and catalytically inactive Cas9 (dCas9). The MIC<sub>99</sub> is the concentration of EPT or RFB that prevented growth relative to the drug free plate.</p></sec><sec id="sec031"><title>Norvaline suppression of mutants</title><p>Early log phase <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> or <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> (OD<sub>600</sub> 0.1&#x02013;0.4) was cultured and resuspended to an OD<sub>600</sub> of 10 (<italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>) or OD<sub>600</sub> of 1 (<italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic>). One hundred &#x003bc;L of culture (approx. 1 X 10<sup>9</sup> CFU for <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> and 1 x 10<sup>6</sup> CFU for <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic>) was plated on solid media containing 10X MIC<sub>90</sub> EPT, 10X MIC<sub>90</sub> EPT + 590 &#x003bc;g/mL norvaline, or 590 &#x003bc;g/mL norvaline. The experiment was repeated with 10X MIC<sub>90</sub> RFB as control. <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> plates were incubated for 5 days at 37&#x000b0;C, <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> plates were incubated for 5 weeks at 37&#x000b0;C. Number of colonies were enumerated to obtain mutation frequencies. Since, mutations are considered rare events, mutation frequency rates between 10X MIC<sub>90</sub> EPT and 10X MIC<sub>90</sub> EPT + 590 &#x003bc;g/mL norvaline were compared using the two Poisson rates.</p><p>The Poisson rate is defined as the number of events divided by the sample size: <italic toggle="yes">&#x003bb;</italic> = <italic toggle="yes">X</italic>/<italic toggle="yes">N</italic></p><p>The rates were compared using the small sample z-test:
<disp-formula id="ppat.1009965.e001">
<alternatives><graphic xlink:href="ppat.1009965.e001.jpg" id="ppat.1009965.e001g" position="anchor"/><mml:math id="M1" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msqrt><mml:msub><mml:mrow><mml:mi>&#x003bb;</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:msqrt><mml:mo>&#x02212;</mml:mo><mml:msqrt><mml:msub><mml:mrow><mml:mi>&#x003bb;</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:msqrt></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:msqrt><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:msqrt></mml:mrow></mml:mfrac></mml:math></alternatives>
</disp-formula></p></sec><sec id="sec032"><title>LC-MS/MS measurement of norvaline in the proteome</title><p>Wildtype, mutant, and complement <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> strains were grown for 12 h or 3 days in 59 &#x003bc;g/mL norvaline or 59 &#x003bc;g/mL valine. Proteins were extracted using an optimized protocol for mass spectrometry follow-up [<xref rid="ppat.1009965.ref067" ref-type="bibr">67</xref>]. Cells were collected, washed with ice-cold PBS, and resuspended in 1mL lysis buffer (50 mM NH<sub>4</sub>HCO<sub>3</sub> pH 7.4, 10 mM MgCl<sub>2</sub>, 0.1% NaN<sub>3</sub>, 1 mM EGTA, 1 x protease inhibitors (Roche), 7 M urea, and 2 M thiourea). Cells were lysed with zirconia beads and the cell lysate was collected and filtered through a 0.22 &#x003bc;m membrane. Proteins were precipitated overnight at 4&#x000b0;C with TCA at 25% (v/v). The precipitate was washed with 1 mL cold acetone and 250 &#x003bc;L cold water. The final wash is only water. The pellet was resuspended in 200 &#x003bc;L resuspension buffer (50 mM NH<sub>4</sub>HCO<sub>3</sub>, 1 M urea). Protein extraction was quantified with the Bradford assay and the quality of proteins was examined on SDS-PAGE. Protein lysates were dissolved in SDS-PAGE reducing buffer and electrophoresed onto a single stacking gel band to remove lipids, detergents and salts. For each sample, a single gel band was reduced with DTT (Sigma), alkylated with iodoacetic acid (Sigma) and digested with LCMS grade trypsin (Promega). Extracted peptides were re-solubilized in 0.1% aqueous formic acid and loaded onto a Thermo Acclaim Pepmap (Thermo, 75 &#x003bc;M ID X 2 cm C18 3 &#x003bc;M beads) precolumn and then onto an Acclaim Pepmap Easyspray (Thermo, 75 &#x003bc;M X 15 cm with 2 &#x003bc;M C18 beads) analytical column separation using a Dionex Ultimate 3000 uHPLC at 250 nl/min with a gradient of 2&#x02013;35% organic (0.1% formic acid in acetonitrile) over 2 hours. Peptides were analyzed using a Thermo Orbitrap Fusion mass spectrometer operating at 120,000 resolution for MS1 with HCD sequencing at top speed (15,000 resolution) for all peptides with a charge of 2+ or greater. The raw data were converted into *.mgf format (Mascot generic format) for searching using the Mascot 2.5.1 search engine (Matrix Science) against Mycobacterium abscessus protein sequences (Uniprot downloaded 2020.11.30). A modification for Xle-&#x0003e;Val was used to detect incorporation of Val into WT sequences. The database search results were loaded onto Scaffold Q+ Scaffold_4.4.8 (Proteome Sciences) for statistical treatment and data visualization.</p></sec><sec id="sec033"><title>Murine model of chronic <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> infection using NOD.CB17-<italic toggle="yes">Prkdc</italic><sup><italic toggle="yes">scid</italic></sup>/NCrCrl mice</title><p>RFB (Sigma), EPT (Cayman Chemical), and norvaline (Sigma) were dissolved in 0.5% w/v sterile low viscosity carboxymethyl cellulose pH 7 (vehicle). Drugs were aliquoted and stored at -20&#x000b0;C for the duration of the 10-day treatment. 6&#x02013;8 weeks-old female mice were ordered from Charles River Labs. Mice were intranasally infected with ~10<sup>6</sup> CFU (25 &#x003bc;L of 5x10<sup>8</sup> CFU/mL) of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> CIP 104536<sup>T</sup> (rough morphotype). Five mice were sacrificed 4 hours post-infection to determine initial lung inoculum and on day 1 to enumerate CFU prior to drug administration. Mice were treated daily by oral gavage with 100 &#x003bc;L of vehicle or drug. On day 11, mice were humanely euthanized, the lungs were collected and homogenized in 1mL of 7H9 complete. Lung homogenates were plated on 7H11 agar and plates were incubated at 37&#x000b0;C for 5 days. CFU data was log-transformed for one-way ANOVA with Tukey&#x02019;s multiple comparisons test using GraphPad Prism version 9.</p></sec></sec><sec id="sec034" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="ppat.1009965.s001" position="float" content-type="local-data"><label>S1 Fig</label><caption><p><bold><italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> phenotypic screening with 176 TB-active compounds from GSK (A-C) and MMV (D-F). A</bold> Luminescence relative to drug free conditions using <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> lux. Data is shown in duplicate. <bold>B-C</bold> Secondary screening of primary hits using REMA on <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977. % bacteria viability relative to drug free conditions. Data is shown as mean &#x000b1; SD from technical triplicates. Dashed red line indicates 10% viability threshold when screened at 10<italic toggle="yes">&#x003bc;</italic>M. Three hits were identified from primary screen however, all three did not pass the secondary screen. No active compounds were identified from this library. <bold>D</bold> MMV Pathogen box and <bold>E</bold> Pandemic response box; luminescence relative to drug free conditions using <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> lux. Data is shown in duplicate. <bold>F</bold> Secondary screening of primary hits using REMA on <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> ATCC 19977. % bacteria viability relative to drug free conditions. Data is shown in technical triplicate. Dashed red line indicates 10% viability threshold when screened at 10<italic toggle="yes">&#x003bc;</italic>M. <bold>G</bold> Correlation between hits from luminescence primary screen and bacterial viability secondary screen. Correlation calculated using non-parametric Spearman correlation. 20 compounds passed the primary screen and 9 passed the secondary screen. Only three compounds were still active after acquiring fresh batch and displayed dose-dependent activity (3/800). EPT in cyan. AMK in blue as positive control. Two negative hits from luminescence screen in magenta used as negative controls. Drug free in black used as media control.</p><p>(TIFF)</p></caption><media xlink:href="ppat.1009965.s001.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="ppat.1009965.s002" position="float" content-type="local-data"><label>S2 Fig</label><caption><title>Isobolograms for potential combination therapy with EPT.</title><p>Green area indicates synergy (FICI &#x0003c; 0.5); red area indicates antagonism (FICI &#x02265; 4.0); white area indicates indifferent. RIF and CLR, and AMK and CLR are used as synergy and antagonism controls, respectively. Data shown is from checkerboard assays done in technical duplicate.</p><p>(TIFF)</p></caption><media xlink:href="ppat.1009965.s002.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="ppat.1009965.s003" position="float" content-type="local-data"><label>S3 Fig</label><caption><title>Drug susceptibility assessment of resistant mutants.</title><p><bold>A-D</bold> Dose-response curves of isolated EPT (10X, 20X, 40X MIC) mutants or AMK (40X MIC) mutant. AMK was used as control compound for mutant isolation. RIF and BDQ were used for cross-resistance verification. ATCC 19977 (black circles), D436H mutant-1 (yellow squares), D436H mutant-2 (pink diamonds), D436H mutant-3 (green triangles), D436H mutant-4 (purple inverted triangles), AMK 40X (crosses). Data is mean &#x000b1; SD from two independent experiments.</p><p>(TIFF)</p></caption><media xlink:href="ppat.1009965.s003.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="ppat.1009965.s004" position="float" content-type="local-data"><label>S4 Fig</label><caption><title>Thermodynamic analysis of EPT binding to LeuRS editing domain.</title><p>Heat of injection (upper panel) and single-site binding model of the integrated isotherm (lower panel). <italic toggle="yes">Mabs</italic> LeuRS (left) or <italic toggle="yes">Mtb</italic> LeuRS (right) editing domains bound to EPT.</p><p>(TIFF)</p></caption><media xlink:href="ppat.1009965.s004.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="ppat.1009965.s005" position="float" content-type="local-data"><label>S5 Fig</label><caption><title>Co-crystal structure of LeuRS and benzoxaborole adducts.</title><p><bold>A</bold> Difference maps for the EPT-AMP adduct in 7N12. Unbiased FO-FC difference maps (2.8<italic toggle="yes">&#x003c3;</italic>), calculated with phases from a model that never included ligand. <bold>B</bold> Comparison of apo (green, PDB 7N11) and co-complex (cyan, PDB 7N12) structures of <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS bound to EPT-AMP. <bold>C</bold> Benzoxaborole inhibitors of LeuRS. (Left) EPT-AMP adduct bound to <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic> LeuRS. (Right) BNZ-AMP adduct bound to <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> LeuRS.</p><p>(TIFF)</p></caption><media xlink:href="ppat.1009965.s005.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="ppat.1009965.s006" position="float" content-type="local-data"><label>S1 Table</label><caption><title>Carbon dependent variability on EPT activity.</title><p>G, Glycerol; A, Acetate; Tw80, Tween-80; CaMH, Cation-adjusted Muller-Hinton.</p><p>(DOCX)</p></caption><media xlink:href="ppat.1009965.s006.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="ppat.1009965.s007" position="float" content-type="local-data"><label>S2 Table</label><caption><title>Epetraborole <italic toggle="yes">in vitro</italic> activity against clinical isolates.</title><p><sup>a</sup>Morphology as determined by smooth (S) or rough (R) colonies on 7H10 agar. Drugs used: EPT, Epetraborole; AMK, Amikacin; RIF, Rifampicin; BDQ, Bedaquiline; CFX, Cefoxitin; CLR, Clarithromycin.</p><p>(DOCX)</p></caption><media xlink:href="ppat.1009965.s007.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="ppat.1009965.s008" position="float" content-type="local-data"><label>S3 Table</label><caption><title>Epetraborole <italic toggle="yes">in vitro</italic> activity spectrum.</title><p><sup>a</sup>Acid fast (AF); gram positive (+); gram negative (-). EPT, Epetraborole; AMK, Amikacin; RIF, Rifampicin; ERV, BDQ, Bedaquiline; CFX, Cefoxitin; CLR, Clarithromycin. Species: <italic toggle="yes">Mycobacterium abscessus</italic>, <italic toggle="yes">Mycobacterium avium hominissuis</italic>, <italic toggle="yes">Mycobacterium avium intracellulaire</italic>, <italic toggle="yes">Mycobacterium tuberculosis</italic> H37Rv, <italic toggle="yes">Mycobacterium tuberculosis</italic> Erdman, <italic toggle="yes">Bacillus cereus</italic>, <italic toggle="yes">Corynebacterium glutamicum</italic>, <italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>.</p><p>(DOCX)</p></caption><media xlink:href="ppat.1009965.s008.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="ppat.1009965.s009" position="float" content-type="local-data"><label>S4 Table</label><caption><title><italic toggle="yes">In vitro</italic> resistance frequency.</title><p><sup>a</sup>N.D: not determined. <sup>b</sup>MIC<sub>90</sub> values on 7H10 agar used in this experiment were 4.0 &#x003bc;g/mL and 0.27 &#x003bc;g/mL for amikacin and epetraborole, respectively.</p><p>(DOCX)</p></caption><media xlink:href="ppat.1009965.s009.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="ppat.1009965.s010" position="float" content-type="local-data"><label>S5 Table</label><caption><title>Primers.</title><p>(DOCX)</p></caption><media xlink:href="ppat.1009965.s010.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="ppat.1009965.s011" position="float" content-type="local-data"><label>S6 Table</label><caption><title>Whole genome sequencing variants identified in EPT-resistant <italic toggle="yes">M</italic>. <italic toggle="yes">abscessus</italic>.</title><p>(DOCX)</p></caption><media xlink:href="ppat.1009965.s011.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="ppat.1009965.s012" position="float" content-type="local-data"><label>S7 Table</label><caption><title>Data collection and refinement statistics.</title><p>(DOCX)</p></caption><media xlink:href="ppat.1009965.s012.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank Adam Hassan (Research Institute of the McGill University Health Centre) for technical assistance with mouse experiments. We thank Medicines for Malaria Venture for providing the MMV Open pathogen box and pandemic response boxes. <italic toggle="yes">This research used resources of the Advanced Photon Source</italic>, <italic toggle="yes">a U</italic>.<italic toggle="yes">S</italic>. <italic toggle="yes">Department of Energy (DOE) Office of Science User Facility</italic>, <italic toggle="yes">operated for the DOE Office of Science by Argonne National Laboratory under Contract No</italic>. <italic toggle="yes">DE-AC02-06CH11357</italic>. <italic toggle="yes">Extraordinary facility operations were supported in part by the DOE Office of Science through the National Virtual Biotechnology Laboratory</italic>, <italic toggle="yes">a consortium of DOE national laboratories focused on the response to COVID-19</italic>, <italic toggle="yes">with funding provided by the Coronavirus CARES Act</italic>. Part or all of the research described in this paper was performed using beamline CMCF-BM at the Canadian Light Source, a national research facility of the University of Saskatchewan, which is supported by the Canada Foundation for Innovation (CFI), the Natural Sciences and Engineering Research Council (NSERC), the National Research Council (NRC), the Canadian Institutes of Health Research (CIHR), the Government of Saskatchewan, and the University of Saskatchewan. The <italic toggle="yes">luxCDABE</italic> plasmid was kindly gifted by Jeffery S. Cox. We are grateful to the CRBM zebrafish facility (Montpellier), P. Richard and M. Plays for zebrafish husbandry.</p></ack><ref-list><title>References</title><ref id="ppat.1009965.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Johansen</surname><given-names>MD</given-names></name>, <name><surname>Herrmann</surname><given-names>J-L</given-names></name>, <name><surname>Kremer</surname><given-names>L</given-names></name>. <article-title>Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus</article-title>. <source>Nat Rev Microbiol</source>. <year>2020</year>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41579-020-0331-1</pub-id>
<?supplied-pmid 32086501?><pub-id pub-id-type="pmid">32086501</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Griffith</surname><given-names>DE</given-names></name>, <name><surname>Aksamit</surname><given-names>T</given-names></name>, <name><surname>Brown-Elliott</surname><given-names>BA</given-names></name>, <name><surname>Catanzaro</surname><given-names>A</given-names></name>, <name><surname>Daley</surname><given-names>C</given-names></name>, <name><surname>Gordin</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2007</year>;<volume>175</volume>: <fpage>367</fpage>&#x02013;<lpage>416</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1164/rccm.200604-571ST</pub-id>
<?supplied-pmid 17277290?><pub-id pub-id-type="pmid">17277290</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Haworth</surname><given-names>CS</given-names></name>, <name><surname>Banks</surname><given-names>J</given-names></name>, <name><surname>Capstick</surname><given-names>T</given-names></name>, <name><surname>Fisher</surname><given-names>AJ</given-names></name>, <name><surname>Gorsuch</surname><given-names>T</given-names></name>, <name><surname>Laurenson</surname><given-names>IF</given-names></name>, <etal>et al</etal>. <article-title>British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)</article-title>. <source>Thorax</source>. <year>2017</year>;<volume>72</volume>: <fpage>ii1</fpage>&#x02013;<lpage>ii64</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/thoraxjnl-2017-210927</pub-id>
<?supplied-pmid 29054853?><pub-id pub-id-type="pmid">29054853</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>MR</given-names></name>, <name><surname>Sheng</surname><given-names>WH</given-names></name>, <name><surname>Hung</surname><given-names>CC</given-names></name>, <name><surname>Yu</surname><given-names>CJ</given-names></name>, <name><surname>Lee</surname><given-names>LN</given-names></name>, <name><surname>Hsueh</surname><given-names>PR</given-names></name>. <article-title>Mycobacterium abscessus complex infections in humans</article-title>. <source>Emerg Infect Dis</source>. <year>2015</year>;<volume>21</volume>: <fpage>1638</fpage>&#x02013;<lpage>1646</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3201/2109.141634</pub-id>
<?supplied-pmid 26295364?><pub-id pub-id-type="pmid">26295364</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Van Ingen</surname><given-names>J</given-names></name>, <name><surname>Boeree</surname><given-names>MJ</given-names></name>, <name><surname>Van Soolingen</surname><given-names>D</given-names></name>, <name><surname>Mouton</surname><given-names>JW</given-names></name>. <article-title>Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria</article-title>. <source>Drug Resist Updat</source>. <year>2012</year>;<volume>15</volume>: <fpage>149</fpage>&#x02013;<lpage>161</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.drup.2012.04.001</pub-id>
<?supplied-pmid 22525524?><pub-id pub-id-type="pmid">22525524</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>ML</given-names></name>, <name><surname>Aziz</surname><given-names>DB</given-names></name>, <name><surname>Dartois</surname><given-names>V</given-names></name>, <name><surname>Dick</surname><given-names>T</given-names></name>. <article-title>NTM drug discovery: status, gaps and the way forward</article-title>. <source>Drug Discov Today</source>. <year>2018</year>;<volume>0</volume>: <fpage>1</fpage>&#x02013;<lpage>18</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.drudis.2018.04.001</pub-id>
<?supplied-pmid 29635026?><pub-id pub-id-type="pmid">29635026</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>TS</given-names></name>, <name><surname>Choe</surname><given-names>JH</given-names></name>, <name><surname>Kim</surname><given-names>YJ</given-names></name>, <name><surname>Yang</surname><given-names>CS</given-names></name>, <name><surname>Kwon</surname><given-names>HJ</given-names></name>, <name><surname>Jeong</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Activity of LCB01-0371, a novel oxazolidinone, against mycobacterium abscessus</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2017</year>;<fpage>61</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.02752-16</pub-id>
<?supplied-pmid 28674049?><pub-id pub-id-type="pmid">28674049</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Le Run</surname><given-names>E</given-names></name>, <name><surname>Arthur</surname><given-names>M</given-names></name>, <name><surname>Mainardia</surname><given-names>JL</given-names></name>. <article-title>In Vitro and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against Mycobacterium abscessus</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2019</year>;<fpage>63</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.01915-18</pub-id>
<?supplied-pmid 30745387?><pub-id pub-id-type="pmid">30745387</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Dupont</surname><given-names>C</given-names></name>, <name><surname>Viljoen</surname><given-names>A</given-names></name>, <name><surname>Dubar</surname><given-names>F</given-names></name>, <name><surname>Blaise</surname><given-names>M</given-names></name>, <name><surname>Bernut</surname><given-names>A</given-names></name>, <name><surname>Pawlik</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus</article-title>. <source>Mol Microbiol</source>. <year>2016</year>;<volume>101</volume>: <fpage>515</fpage>&#x02013;<lpage>529</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/mmi.13406</pub-id>
<?supplied-pmid 27121350?><pub-id pub-id-type="pmid">27121350</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Kozikowski</surname><given-names>AP</given-names></name>, <name><surname>Onajole</surname><given-names>OK</given-names></name>, <name><surname>Stec</surname><given-names>J</given-names></name>, <name><surname>Dupont</surname><given-names>C</given-names></name>, <name><surname>Viljoen</surname><given-names>A</given-names></name>, <name><surname>Richard</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections</article-title>. <source>J Med Chem</source>. <year>2017</year>;<volume>60</volume>: <fpage>5876</fpage>&#x02013;<lpage>5888</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00582</pub-id>
<?supplied-pmid 28574259?><pub-id pub-id-type="pmid">28574259</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Rock</surname><given-names>FL</given-names></name>, <name><surname>Mao</surname><given-names>W</given-names></name>, <name><surname>Yaremchuk</surname><given-names>A</given-names></name>, <name><surname>Tukalo</surname><given-names>M</given-names></name>, <name><surname>Cr&#x000e9;pin</surname><given-names>T</given-names></name>, <name><surname>Zhou</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site</article-title>. <source>Science (80-)</source>. <year>2007</year>;<volume>316</volume>: <fpage>1759</fpage>&#x02013;<lpage>1761</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.1142189</pub-id>
<?supplied-pmid 17588934?><pub-id pub-id-type="pmid">17588934</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Baker</surname><given-names>SJ</given-names></name>, <name><surname>Zhang</surname><given-names>YK</given-names></name>, <name><surname>Akama</surname><given-names>T</given-names></name>, <name><surname>Lau</surname><given-names>A</given-names></name>, <name><surname>Zhou</surname><given-names>H</given-names></name>, <name><surname>Hernandez</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro- 1-hydroxy-2,1-benzoxaborole (AN2690), for the potential treatment of onychomycosis</article-title>. <source>J Med Chem</source>. <year>2006</year>;<volume>49</volume>: <fpage>4447</fpage>&#x02013;<lpage>4450</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/jm0603724</pub-id>
<?supplied-pmid 16854048?><pub-id pub-id-type="pmid">16854048</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Nureki</surname><given-names>O</given-names></name>, <name><surname>Vassylyev</surname><given-names>DG</given-names></name>, <name><surname>Tateno</surname><given-names>M</given-names></name>, <name><surname>Shimada</surname><given-names>A</given-names></name>, <name><surname>Nakama</surname><given-names>T</given-names></name>, <name><surname>Fukai</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Enzyme structure with two catalytic sites for double-sieve selection of substrate</article-title>. <source>Science (80-)</source>. <year>1998</year>;<volume>280</volume>: <fpage>578</fpage>&#x02013;<lpage>582</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.280.5363.578</pub-id>
<?supplied-pmid 9554847?><pub-id pub-id-type="pmid">9554847</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Nangle</surname><given-names>LA</given-names></name>, <name><surname>Motta</surname><given-names>CM</given-names></name>, <name><surname>Schimmel</surname><given-names>P</given-names></name>. <article-title>Global Effects of Mistranslation from an Editing Defect in Mammalian Cells</article-title>. <source>Chem Biol</source>. <year>2006</year>;<volume>13</volume>: <fpage>1091</fpage>&#x02013;<lpage>1100</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.chembiol.2006.08.011</pub-id>
<?supplied-pmid 17052613?><pub-id pub-id-type="pmid">17052613</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Penn</surname><given-names>BH</given-names></name>, <name><surname>Netter</surname><given-names>Z</given-names></name>, <name><surname>Johnson</surname><given-names>JR</given-names></name>, <name><surname>Von Dollen</surname><given-names>J</given-names></name>, <name><surname>Jang</surname><given-names>GM</given-names></name>, <name><surname>Johnson</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>An Mtb-Human Protein-Protein Interaction Map Identifies a Switch between Host Antiviral and Antibacterial Responses</article-title>. <source>Mol Cell</source>. <year>2018</year>;<volume>71</volume>: <fpage>637</fpage>&#x02013;<lpage>648.e5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.molcel.2018.07.010</pub-id>
<?supplied-pmid 30118682?><pub-id pub-id-type="pmid">30118682</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Pethe</surname><given-names>K</given-names></name>, <name><surname>Sequeira</surname><given-names>PC</given-names></name>, <name><surname>Agarwalla</surname><given-names>S</given-names></name>, <name><surname>Rhee</surname><given-names>K</given-names></name>, <name><surname>Kuhen</surname><given-names>K</given-names></name>, <name><surname>Phong</surname><given-names>WY</given-names></name>, <etal>et al</etal>. <article-title>A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy</article-title>. <source>Nat Commun</source>. <year>2010</year>;<volume>1</volume>: <fpage>57</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ncomms1060</pub-id>
<?supplied-pmid 20975714?><pub-id pub-id-type="pmid">20975714</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Aziz</surname><given-names>DB</given-names></name>, <name><surname>Low</surname><given-names>JL</given-names></name>, <name><surname>Wu</surname><given-names>ML</given-names></name>, <name><surname>Gengenbacher</surname><given-names>M</given-names></name>, <name><surname>Teo</surname><given-names>JWP</given-names></name>, <name><surname>Dartois</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Rifabutin Is active against mycobacterium abscessus complex</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2017</year>;<fpage>61</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.00155-17</pub-id>
<?supplied-pmid 28396540?><pub-id pub-id-type="pmid">28396540</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Fass</surname><given-names>RJ</given-names></name>, <name><surname>Barnishan</surname><given-names>J</given-names></name>. <article-title>Effect of divalent cation concentrations on the antibiotic susceptibilities of nonfermenters other than Pseudomonas aeruginosa</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1979</year>;<volume>16</volume>: <fpage>434</fpage>&#x02013;<lpage>438</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.16.4.434</pub-id>
<?supplied-pmid 117746?><pub-id pub-id-type="pmid">117746</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Palencia</surname><given-names>A</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Bu</surname><given-names>W</given-names></name>, <name><surname>Choi</surname><given-names>W</given-names></name>, <name><surname>Ding</surname><given-names>CZ</given-names></name>, <name><surname>Easom</surname><given-names>EE</given-names></name>, <etal>et al</etal>. <article-title>Discovery of novel oral protein synthesis inhibitors of mycobacterium tuberculosis that target leucyl-tRNA synthetase</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2016</year>;<volume>60</volume>: <fpage>6271</fpage>&#x02013;<lpage>6280</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.01339-16</pub-id>
<?supplied-pmid 27503647?><pub-id pub-id-type="pmid">27503647</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Maurer</surname><given-names>FP</given-names></name>, <name><surname>Bruderer</surname><given-names>VL</given-names></name>, <name><surname>Ritter</surname><given-names>C</given-names></name>, <name><surname>Castelberg</surname><given-names>C</given-names></name>, <name><surname>Bloemberg G</surname><given-names>V</given-names></name>, <name><surname>B&#x000f6;ttger</surname><given-names>EC</given-names></name>. <article-title>Lack of antimicrobial bactericidal activity in Mycobacterium abscessus</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>: <fpage>3828</fpage>&#x02013;<lpage>3836</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.02448-14</pub-id>
<?supplied-pmid 24752273?><pub-id pub-id-type="pmid">24752273</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Richard</surname><given-names>M</given-names></name>, <name><surname>Guti&#x000e9;rrez</surname><given-names>AV</given-names></name>, <name><surname>Kremer</surname><given-names>L</given-names></name>. <article-title>Dissecting erm(41)-mediated macrolide-inducible resistance in mycobacterium abscessus</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2020</year>;<volume>64</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.01879-19</pub-id>
<?supplied-pmid 31791943?><pub-id pub-id-type="pmid">31791943</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Nash</surname><given-names>KA</given-names></name>, <name><surname>Brown-Elliott</surname><given-names>AB</given-names></name>, <name><surname>Wallace</surname><given-names>RJ</given-names></name>. <article-title>A Novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of mycobacterium abscessus but is absent from mycobacterium chelonae</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2009</year>;<volume>53</volume>: <fpage>1367</fpage>&#x02013;<lpage>1376</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.01275-08</pub-id>
<?supplied-pmid 19171799?><pub-id pub-id-type="pmid">19171799</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Pryjma</surname><given-names>M</given-names></name>, <name><surname>Burian</surname><given-names>J</given-names></name>, <name><surname>Kuchinski</surname><given-names>K</given-names></name>, <name><surname>Thompson</surname><given-names>CJ</given-names></name>. <article-title>Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections is Mediated by the whiB7 gene</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2017</year>;<fpage>61</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.01353-17</pub-id>
<?supplied-pmid 28874379?><pub-id pub-id-type="pmid">28874379</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Aziz</surname><given-names>DB</given-names></name>, <name><surname>Go</surname><given-names>ML</given-names></name>, <name><surname>Dick</surname><given-names>T</given-names></name>. <article-title>Rifabutin Suppresses Inducible Clarithromycin Resistance in Mycobacterium abscessus by Blocking Induction of whiB7 and erm41</article-title>. <source>Antibiotics</source>. <year>2020</year>;<fpage>9</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/antibiotics10010009</pub-id>
<?supplied-pmid 33374204?><pub-id pub-id-type="pmid">33374204</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Bernut</surname><given-names>A</given-names></name>, <name><surname>Herrmann</surname><given-names>J-L</given-names></name>, <name><surname>Ordway</surname><given-names>D</given-names></name>, <name><surname>Kremer</surname><given-names>L</given-names></name>. <article-title>The Diverse Cellular and Animal Models to Decipher the Physiopathological Traits of Mycobacterium abscessus Infection</article-title>. <source>Front Cell Infect Microbiol</source>. <year>2017</year>;<fpage>7</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fcimb.2017.00007</pub-id>
<?supplied-pmid 28164039?><pub-id pub-id-type="pmid">28164039</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Bernut</surname><given-names>A</given-names></name>, <name><surname>Dupont</surname><given-names>C</given-names></name>, <name><surname>Ogryzko N</surname><given-names>V</given-names></name>, <name><surname>Neyret</surname><given-names>A</given-names></name>, <name><surname>Herrmann</surname><given-names>JL</given-names></name>, <name><surname>Floto</surname><given-names>RA</given-names></name>, <etal>et al</etal>. <article-title>CFTR Protects against Mycobacterium abscessus Infection by Fine-Tuning Host Oxidative Defenses</article-title>. <source>Cell Rep</source>. <year>2019</year>;<volume>26</volume>: <fpage>1828</fpage>&#x02013;<lpage>1840</lpage>.e4. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.celrep.2019.01.071</pub-id>
<?supplied-pmid 30759393?><pub-id pub-id-type="pmid">30759393</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Bernut</surname><given-names>A</given-names></name>, <name><surname>Herrmann</surname><given-names>JL</given-names></name>, <name><surname>Kissa</surname><given-names>K</given-names></name>, <name><surname>Dubremetz</surname><given-names>JF</given-names></name>, <name><surname>Gaillard</surname><given-names>JL</given-names></name>, <name><surname>Lutfalla</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Mycobacterium abscessus cording prevents phagocytosis and promotes abscess formation</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2014</year>;<fpage>111</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.1313318110</pub-id>
<?supplied-pmid 24324143?><pub-id pub-id-type="pmid">24324143</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Hernandez</surname><given-names>V</given-names></name>, <name><surname>Cr&#x000e9;pin</surname><given-names>T</given-names></name>, <name><surname>Palencia</surname><given-names>A</given-names></name>, <name><surname>Cusack</surname><given-names>S</given-names></name>, <name><surname>Akama</surname><given-names>T</given-names></name>, <name><surname>Baker</surname><given-names>SJ</given-names></name>, <etal>et al</etal>. <article-title>Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2013</year>;<volume>57</volume>: <fpage>1394</fpage>&#x02013;<lpage>1403</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.02058-12</pub-id>
<?supplied-pmid 23295920?><pub-id pub-id-type="pmid">23295920</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Lincecum</surname><given-names>TL</given-names></name>, <name><surname>Tukalo</surname><given-names>M</given-names></name>, <name><surname>Yaremchuk</surname><given-names>A</given-names></name>, <name><surname>Mursinna</surname><given-names>RS</given-names></name>, <name><surname>Williams</surname><given-names>AM</given-names></name>, <name><surname>Sproat</surname><given-names>BS</given-names></name>, <etal>et al</etal>. <article-title>Structural and mechanistic basis of pre- and posttransfer editing by leucyl-tRNA synthetase</article-title>. <source>Mol Cell</source>. <year>2003</year>;<volume>11</volume>: <fpage>951</fpage>&#x02013;<lpage>963</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s1097-2765(03)00098-4</pub-id>
<?supplied-pmid 12718881?><pub-id pub-id-type="pmid">12718881</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>O&#x02019;Dwyer</surname><given-names>K</given-names></name>, <name><surname>Spivak</surname><given-names>AT</given-names></name>, <name><surname>Ingraham</surname><given-names>K</given-names></name>, <name><surname>Min</surname><given-names>S</given-names></name>, <name><surname>Holmes</surname><given-names>DJ</given-names></name>, <name><surname>Jakielaszek</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2015</year>;<volume>59</volume>: <fpage>289</fpage>&#x02013;<lpage>298</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.03774-14</pub-id>
<?supplied-pmid 25348524?><pub-id pub-id-type="pmid">25348524</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Rock</surname><given-names>JM</given-names></name>, <name><surname>Hopkins</surname><given-names>FF</given-names></name>, <name><surname>Chavez</surname><given-names>A</given-names></name>, <name><surname>Diallo</surname><given-names>M</given-names></name>, <name><surname>Chase</surname><given-names>MR</given-names></name>, <name><surname>Gerrick</surname><given-names>ER</given-names></name>, <etal>et al</etal>. <article-title>Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform</article-title>. <source>Nat Microbiol</source>. <year>2017</year>;<volume>2</volume>: <fpage>16274</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.274</pub-id>
<?supplied-pmid 28165460?><pub-id pub-id-type="pmid">28165460</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Zhai</surname><given-names>Y</given-names></name>, <name><surname>Martinis</surname><given-names>SA</given-names></name>. <article-title>Two conserved threonines collaborate in the Escherichia coli Leucyl-tRNA synthetase amino acid editing mechanism</article-title>. <source>Biochemistry</source>. <year>2005</year>;<volume>44</volume>: <fpage>15437</fpage>&#x02013;<lpage>15443</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/bi0514461</pub-id>
<?supplied-pmid 16300391?><pub-id pub-id-type="pmid">16300391</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Alvarez-Carre&#x000f1;o</surname><given-names>C</given-names></name>, <name><surname>Becerra</surname><given-names>A</given-names></name>, <name><surname>Lazcano</surname><given-names>A</given-names></name>. <article-title>Norvaline and Norleucine May Have Been More Abundant Protein Components during Early Stages of Cell Evolution</article-title>. <source>Orig Life Evol Biosph</source>. <year>2013</year>;<volume>43</volume>: <fpage>363</fpage>&#x02013;<lpage>375</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11084-013-9344-3</pub-id>
<?supplied-pmid 24013929?><pub-id pub-id-type="pmid">24013929</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Ji</surname><given-names>QQ</given-names></name>, <name><surname>Fang</surname><given-names>ZP</given-names></name>, <name><surname>Ye</surname><given-names>Q</given-names></name>, <name><surname>Chi</surname><given-names>CW</given-names></name>, <name><surname>Wang</surname><given-names>ED</given-names></name>. <article-title>Self-protective responses to norvaline-induced stress in a leucyl-tRNA synthetase editing-deficient yeast strain</article-title>. <source>Nucleic Acids Res</source>. <year>2017</year>;<volume>45</volume>: <fpage>7367</fpage>&#x02013;<lpage>7381</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkx487</pub-id>
<?supplied-pmid 28575390?><pub-id pub-id-type="pmid">28575390</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Cvetesic</surname><given-names>N</given-names></name>, <name><surname>Palencia</surname><given-names>A</given-names></name>, <name><surname>Halasz</surname><given-names>I</given-names></name>, <name><surname>Cusack</surname><given-names>S</given-names></name>, <name><surname>Gruic-Sovulj</surname><given-names>I</given-names></name>. <article-title>The physiological target for Leu RS translational quality control is norvaline</article-title>. <source>EMBO J</source>. <year>2014</year>;<volume>33</volume>: <fpage>1639</fpage>&#x02013;<lpage>1653</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.15252/embj.201488199</pub-id>
<?supplied-pmid 24935946?><pub-id pub-id-type="pmid">24935946</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Bacher</surname><given-names>JM</given-names></name>, <name><surname>Schimmel</surname><given-names>P</given-names></name>. <article-title>An editing-defective aminoacyl-tRNA synthetase is mutagenic in aging bacteria via the SOS response</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2007</year>;<volume>104</volume>: <fpage>1907</fpage>&#x02013;<lpage>1912</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.0610835104</pub-id>
<?supplied-pmid 17264207?><pub-id pub-id-type="pmid">17264207</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>Y</given-names></name>, <name><surname>Zhou</surname><given-names>H</given-names></name>, <name><surname>Vo</surname><given-names>MN</given-names></name>, <name><surname>Shi</surname><given-names>Y</given-names></name>, <name><surname>Nawaz</surname><given-names>MH</given-names></name>, <name><surname>Vargas-Rodriguez</surname><given-names>O</given-names></name>, <etal>et al</etal>. <article-title>Double mimicry evades tRNA synthetase editing by toxic vegetable-sourced non-proteinogenic amino acid</article-title>. <source>Nat Commun</source>. <year>2017</year>;<fpage>8</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-017-00021-9</pub-id>
<?supplied-pmid 28364116?><pub-id pub-id-type="pmid">28364116</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>J</given-names></name>, <name><surname>Bergert</surname><given-names>M</given-names></name>, <name><surname>Walther</surname><given-names>A</given-names></name>, <name><surname>Suter</surname><given-names>B</given-names></name>. <article-title>Double-sieving-defective aminoacyl-tRNA synthetase causes protein mistranslation and affects cellular physiology and development</article-title>. <source>Nat Commun</source>. <year>2014</year>;<fpage>5</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ncomms6650</pub-id>
<?supplied-pmid 25427601?><pub-id pub-id-type="pmid">25427601</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>JW</given-names></name>, <name><surname>Beebe</surname><given-names>K</given-names></name>, <name><surname>Nangle</surname><given-names>LA</given-names></name>, <name><surname>Jang</surname><given-names>J</given-names></name>, <name><surname>Longo-Guess</surname><given-names>CM</given-names></name>, <name><surname>Cook</surname><given-names>SA</given-names></name>, <etal>et al</etal>. <article-title>Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration</article-title>. <source>Nature</source>. <year>2006</year>;<volume>443</volume>: <fpage>50</fpage>&#x02013;<lpage>55</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature05096</pub-id>
<?supplied-pmid 16906134?><pub-id pub-id-type="pmid">16906134</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Schimmel</surname><given-names>P</given-names></name>. <article-title>Mistranslation and its control by tRNA synthetases</article-title>. <source>Philos Trans R Soc B Biol Sci</source>. <year>2011</year>;<volume>366</volume>: <fpage>2965</fpage>&#x02013;<lpage>2971</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1098/rstb.2011.0158</pub-id>
<?supplied-pmid 21930589?><pub-id pub-id-type="pmid">21930589</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Dick</surname><given-names>T</given-names></name>, <name><surname>Shin</surname><given-names>SJ</given-names></name>, <name><surname>Koh</surname><given-names>WJ</given-names></name>, <name><surname>Dartois</surname><given-names>V</given-names></name>, <name><surname>Gengenbacher</surname><given-names>M</given-names></name>. <article-title>Rifabutin is active against mycobacterium abscessus in mice</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2020</year>;<volume>64</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.01943-19</pub-id>
<?supplied-pmid 31767722?><pub-id pub-id-type="pmid">31767722</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Polis</surname><given-names>B</given-names></name>, <name><surname>Srikanth</surname><given-names>KD</given-names></name>, <name><surname>Gurevich</surname><given-names>V</given-names></name>, <name><surname>Gil-Henn</surname><given-names>H</given-names></name>, <name><surname>Samson</surname><given-names>AO</given-names></name>. <article-title>L-Norvaline, a new therapeutic agent against Alzheimer&#x02019;s disease</article-title>. <source>Neural Regen Res</source>. <year>2019</year>;<volume>14</volume>: <fpage>1562</fpage>&#x02013;<lpage>1572</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4103/1673-5374.255980</pub-id>
<?supplied-pmid 31089055?><pub-id pub-id-type="pmid">31089055</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Ganapathy</surname><given-names>US</given-names></name>, <name><surname>Gengenbacher</surname><given-names>M</given-names></name>, <name><surname>Dick</surname><given-names>T</given-names></name>. <article-title>Epetraborole is Active against Mycobacterium abscessus</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2021</year> [cited 31 Aug 2021]. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.01156-21</pub-id>
<?supplied-pmid 34280020?><pub-id pub-id-type="pmid">34280020</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>T</given-names></name>, <name><surname>Hanh</surname><given-names>BTB</given-names></name>, <name><surname>Heo</surname><given-names>B</given-names></name>, <name><surname>Quang</surname><given-names>N</given-names></name>, <name><surname>Park</surname><given-names>Y</given-names></name>, <name><surname>Shin</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>A screening of the mmv pandemic response box reveals epetraborole as a new potent inhibitor against mycobacterium abscessus</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<fpage>22</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms22115936</pub-id>
<?supplied-pmid 34073006?><pub-id pub-id-type="pmid">34073006</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Melnikov S</surname><given-names>V</given-names></name>, <name><surname>Stevens</surname><given-names>DL</given-names></name>, <name><surname>Fu</surname><given-names>X</given-names></name>, <name><surname>Kwok</surname><given-names>HS</given-names></name>, <name><surname>Zhang</surname><given-names>JT</given-names></name>, <name><surname>Shen</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Exploiting evolutionary trade-offs for posttreatment management of drug-resistant populations</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2020</year>;<volume>117</volume>: <fpage>17924</fpage>&#x02013;<lpage>17931</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.2003132117</pub-id>
<?supplied-pmid 32661175?><pub-id pub-id-type="pmid">32661175</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Reingewertz</surname><given-names>TH</given-names></name>, <name><surname>Meyer</surname><given-names>T</given-names></name>, <name><surname>McIntosh</surname><given-names>F</given-names></name>, <name><surname>Sullivan</surname><given-names>J</given-names></name>, <name><surname>Meir</surname><given-names>M</given-names></name>, <name><surname>Chang</surname><given-names>YF</given-names></name>, <etal>et al</etal>. <article-title>Differential sensitivity of mycobacteria to isoniazid is related to differences in katg-mediated enzymatic activation of the drug</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2020</year>;<fpage>64</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.01899-19</pub-id>
<?supplied-pmid 31767723?><pub-id pub-id-type="pmid">31767723</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Rominski</surname><given-names>A</given-names></name>, <name><surname>Roditscheff</surname><given-names>A</given-names></name>, <name><surname>Selchow</surname><given-names>P</given-names></name>, <name><surname>B&#x000f6;ttger</surname><given-names>EC</given-names></name>, <name><surname>Sander</surname><given-names>P</given-names></name>. <article-title>Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591</article-title>. <source>J Antimicrob Chemother</source>. <year>2017</year>;<volume>72</volume>: <fpage>376</fpage>&#x02013;<lpage>384</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/jac/dkw466</pub-id>
<?supplied-pmid 27999011?><pub-id pub-id-type="pmid">27999011</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Luthra</surname><given-names>S</given-names></name>, <name><surname>Rominski</surname><given-names>A</given-names></name>, <name><surname>Sander</surname><given-names>P</given-names></name>. <article-title>The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in Mycobacterium abscessus Drug Resistance</article-title>. <source>Front Microbiol</source>. <year>2018</year>;<fpage>9</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fmicb.2018.00009</pub-id>
<?supplied-pmid 29387050?><pub-id pub-id-type="pmid">29387050</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Alcaide</surname><given-names>F</given-names></name>, <name><surname>Pfyffer</surname><given-names>GE</given-names></name>, <name><surname>Telenti</surname><given-names>A</given-names></name>. <article-title>Role of embB in natural and acquired resistance to ethambutol in mycobacteria</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1997</year>;<volume>41</volume>: <fpage>2270</fpage>&#x02013;<lpage>2273</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.41.10.2270</pub-id>
<?supplied-pmid 9333060?><pub-id pub-id-type="pmid">9333060</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>Z</given-names></name>, <name><surname>Scorpio</surname><given-names>A</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>. <article-title>The pncA gene from naturally pyrarinamide-resistant Mycobacterium avium encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant M. tuberculosis complex organisms</article-title>. <source>Microbiology</source>. <year>1997</year>;<volume>143</volume>: <fpage>3367</fpage>&#x02013;<lpage>3373</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1099/00221287-143-10-3367</pub-id>
<?supplied-pmid 9353938?><pub-id pub-id-type="pmid">9353938</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Scorpio</surname><given-names>A</given-names></name>, <name><surname>Nikaido</surname><given-names>H</given-names></name>, <name><surname>Sun</surname><given-names>Z</given-names></name>. <article-title>Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide</article-title>. <source>J Bacteriol</source>. <year>1999</year>;<volume>181</volume>: <fpage>2044</fpage>&#x02013;<lpage>2049</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/JB.181.7.2044-2049.1999</pub-id>
<?supplied-pmid 10094680?><pub-id pub-id-type="pmid">10094680</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Su</surname><given-names>H</given-names></name>, <name><surname>Xu</surname><given-names>Y</given-names></name>. <article-title>Application of ITC-based characterization of thermodynamic and kinetic association of ligands with proteins in drug design</article-title>. <source>Front Pharmacol</source>. <year>2018</year>;<volume>9</volume>: <fpage>1</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fphar.2018.00001</pub-id>
<?supplied-pmid 29387012?><pub-id pub-id-type="pmid">29387012</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Dub&#x000e9;e</surname><given-names>V</given-names></name>, <name><surname>Bernut</surname><given-names>A</given-names></name>, <name><surname>Cortes</surname><given-names>M</given-names></name>, <name><surname>Lesne</surname><given-names>T</given-names></name>, <name><surname>Dorchene</surname><given-names>D</given-names></name>, <name><surname>Lefebvre</surname><given-names>AL</given-names></name>, <etal>et al</etal>. <article-title>&#x003b2;-Lactamase inhibition by avibactam in Mycobacterium abscessus</article-title>. <source>J Antimicrob Chemother</source>. <year>2014</year>;<volume>70</volume>: <fpage>1051</fpage>&#x02013;<lpage>1058</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/jac/dku510</pub-id>
<?supplied-pmid 25525201?><pub-id pub-id-type="pmid">25525201</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Ming</surname><given-names>XF</given-names></name>, <name><surname>Rajapakse</surname><given-names>AG</given-names></name>, <name><surname>Carvas</surname><given-names>JM</given-names></name>, <name><surname>Ruffieux</surname><given-names>J</given-names></name>, <name><surname>Yang</surname><given-names>Z</given-names></name>. <article-title>Inhibition of S6K1 accounts partially for the anti-inflammatory effects of the arginase inhibitor L-norvaline</article-title>. <source>BMC Cardiovasc Disord</source>. <year>2009</year>;<fpage>9</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1471-2261-9-9</pub-id>
<?supplied-pmid 19254382?><pub-id pub-id-type="pmid">19254382</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>C-I</given-names></name>, <name><surname>Liao</surname><given-names>JC</given-names></name>, <name><surname>Kuo</surname><given-names>L</given-names></name>. <article-title>Arginase modulates nitric oxide production in activated macrophages</article-title>. <source>Am J Physiol</source>. <year>1998</year>;<volume>274</volume>: <fpage>H324</fpage>&#x02013;<lpage>H348</lpage>. Available: <ext-link xlink:href="https://journals.physiology.org/doi/pdf/10.1152/ajpheart.1998.274.1.H342" ext-link-type="uri">https://journals.physiology.org/doi/pdf/10.1152/ajpheart.1998.274.1.H342</ext-link>
<?supplied-pmid 9458885?><pub-id pub-id-type="pmid">9458885</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Ballell</surname><given-names>L</given-names></name>, <name><surname>Bates</surname><given-names>RH</given-names></name>, <name><surname>Young</surname><given-names>RJ</given-names></name>, <name><surname>Alvarez-Gomez</surname><given-names>D</given-names></name>, <name><surname>Alvarez-Ruiz</surname><given-names>E</given-names></name>, <name><surname>Barroso</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis</article-title>. <source>ChemMedChem</source>. <year>2013</year>;<volume>8</volume>: <fpage>313</fpage>&#x02013;<lpage>321</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/cmdc.201200428</pub-id>
<?supplied-pmid 23307663?><pub-id pub-id-type="pmid">23307663</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Lamason</surname><given-names>RL</given-names></name>, <name><surname>Mohideen</surname><given-names>MAPK</given-names></name>, <name><surname>Mest</surname><given-names>JR</given-names></name>, <name><surname>Wong</surname><given-names>AC</given-names></name>, <name><surname>Norton -Heather</surname><given-names>L</given-names></name>, <name><surname>Aros</surname><given-names>MC</given-names></name>, <etal>et al</etal>. <article-title>Genetics: SLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans</article-title>. <source>Science (80-)</source>. <year>2005</year>;<volume>310</volume>: <fpage>1782</fpage>&#x02013;<lpage>1786</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.1116238</pub-id>
<?supplied-pmid 16357253?><pub-id pub-id-type="pmid">16357253</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Bernut</surname><given-names>A</given-names></name>, <name><surname>Dupont</surname><given-names>C</given-names></name>, <name><surname>Sahuquet</surname><given-names>A</given-names></name>, <name><surname>Herrmann</surname><given-names>JL</given-names></name>, <name><surname>Lutfalla</surname><given-names>G</given-names></name>, <name><surname>Kremer</surname><given-names>L</given-names></name>. <article-title>Deciphering and imaging pathogenesis and cording of Mycobacterium abscessus in zebrafish embryos</article-title>. <source>J Vis Exp</source>. <year>2015</year>;<volume>2015</volume>: <fpage>53130</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3791/53130</pub-id>
<?supplied-pmid 26382225?><pub-id pub-id-type="pmid">26382225</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Bernut</surname><given-names>A</given-names></name>, <name><surname>Le Moigne</surname><given-names>V</given-names></name>, <name><surname>Lesne</surname><given-names>T</given-names></name>, <name><surname>Lutfalla</surname><given-names>G</given-names></name>, <name><surname>Herrmann</surname><given-names>JL</given-names></name>, <name><surname>Kremer</surname><given-names>L</given-names></name>. <article-title>In Vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>: <fpage>4054</fpage>&#x02013;<lpage>4063</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/AAC.00142-14</pub-id>
<?supplied-pmid 24798271?><pub-id pub-id-type="pmid">24798271</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Otwinowski</surname><given-names>Z</given-names></name>, <name><surname>Minor</surname><given-names>W</given-names></name>. <article-title>Processing of X-ray diffraction data collected in oscillation mode</article-title>. <source>Methods Enzymol</source>. <year>1997</year>;<volume>276</volume>: <fpage>307</fpage>&#x02013;<lpage>326</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0076-6879(97)76066-X</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Beilsten-Edmands</surname><given-names>J</given-names></name>, <name><surname>Winter</surname><given-names>G</given-names></name>, <name><surname>Gildea</surname><given-names>R</given-names></name>, <name><surname>Parkhurst</surname><given-names>J</given-names></name>, <name><surname>Waterman</surname><given-names>D</given-names></name>, <name><surname>Evans</surname><given-names>G</given-names></name>. <article-title>Scaling diffraction data in the DIALS software package: Algorithms and new approaches for multi-crystal scaling</article-title>. <source>Acta Crystallogr Sect D Struct Biol</source>. <year>2020</year>;<volume>76</volume>: <fpage>385</fpage>&#x02013;<lpage>399</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1107/S2059798320003198</pub-id>
<?supplied-pmid 32254063?><pub-id pub-id-type="pmid">32254063</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Bunk&#x000f3;czi</surname><given-names>G</given-names></name>, <name><surname>Echols</surname><given-names>N</given-names></name>, <name><surname>McCoy</surname><given-names>AJ</given-names></name>, <name><surname>Oeffner</surname><given-names>RD</given-names></name>, <name><surname>Adams</surname><given-names>PD</given-names></name>, <name><surname>Read</surname><given-names>RJ</given-names></name>. <article-title>Phaser.MRage: Automated molecular replacement</article-title>. <source>Acta Crystallogr Sect D Biol Crystallogr</source>. <year>2013</year>;<volume>69</volume>: <fpage>2276</fpage>&#x02013;<lpage>2286</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1107/S0907444913022750</pub-id>
<?supplied-pmid 24189240?><pub-id pub-id-type="pmid">24189240</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Afonine P</surname><given-names>V</given-names></name>, <name><surname>Poon</surname><given-names>BK</given-names></name>, <name><surname>Read</surname><given-names>RJ</given-names></name>, <name><surname>Sobolev O</surname><given-names>V</given-names></name>, <name><surname>Terwilliger</surname><given-names>TC</given-names></name>, <name><surname>Urzhumtsev</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Real-space refinement in PHENIX for cryo-EM and crystallography</article-title>. <source>Acta Crystallogr Sect D Struct Biol</source>. <year>2018</year>;<volume>74</volume>: <fpage>531</fpage>&#x02013;<lpage>544</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1107/S2059798318006551</pub-id>
<?supplied-pmid 29872004?><pub-id pub-id-type="pmid">29872004</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Emsley</surname><given-names>P</given-names></name>, <name><surname>Lohkamp</surname><given-names>B</given-names></name>, <name><surname>Scott</surname><given-names>WG</given-names></name>, <name><surname>Cowtan</surname><given-names>K</given-names></name>. <article-title>Features and development of Coot</article-title>. <source>Acta Crystallogr Sect D Biol Crystallogr</source>. <year>2010</year>;<volume>66</volume>: <fpage>486</fpage>&#x02013;<lpage>501</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id>
<?supplied-pmid 20383002?><pub-id pub-id-type="pmid">20383002</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Moriarty</surname><given-names>NW</given-names></name>, <name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name>, <name><surname>Adams</surname><given-names>PD</given-names></name>. <article-title>Electronic ligand builder and optimization workbench (eLBOW): A tool for ligand coordinate and restraint generation</article-title>. <source>Acta Crystallogr Sect D Biol Crystallogr</source>. <year>2009</year>;<volume>65</volume>: <fpage>1074</fpage>&#x02013;<lpage>1080</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1107/S0907444909029436</pub-id>
<?supplied-pmid 19770504?><pub-id pub-id-type="pmid">19770504</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Long</surname><given-names>F</given-names></name>, <name><surname>Nicholls</surname><given-names>RA</given-names></name>, <name><surname>Emsley</surname><given-names>P</given-names></name>, <name><surname>Gra&#x0017e;ulis</surname><given-names>S</given-names></name>, <name><surname>Merkys</surname><given-names>A</given-names></name>, <name><surname>Vaitkus</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>AceDRG: A stereochemical description generator for ligands</article-title>. <source>Acta Crystallogr Sect D Struct Biol</source>. <year>2017</year>;<volume>73</volume>: <fpage>112</fpage>&#x02013;<lpage>122</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1107/S2059798317000067</pub-id>
<?supplied-pmid 28177307?><pub-id pub-id-type="pmid">28177307</pub-id></mixed-citation></ref><ref id="ppat.1009965.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Rabodoarivelo</surname><given-names>MS</given-names></name>, <name><surname>Aerts</surname><given-names>M</given-names></name>, <name><surname>Vandamme</surname><given-names>P</given-names></name>, <name><surname>Palomino</surname><given-names>JC</given-names></name>, <name><surname>Rasolofo</surname><given-names>V</given-names></name>, <name><surname>Martin</surname><given-names>A</given-names></name>. <article-title>Optimizing of a protein extraction method for Mycobacterium tuberculosis proteome analysis using mass spectrometry</article-title>. <source>J Microbiol Methods</source>. <year>2016</year>;<volume>131</volume>: <fpage>144</fpage>&#x02013;<lpage>147</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.mimet.2016.10.021</pub-id>
<?supplied-pmid 27984057?><pub-id pub-id-type="pmid">27984057</pub-id></mixed-citation></ref></ref-list></back><sub-article article-type="aggregated-review-documents" id="ppat.1009965.r001" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.ppat.1009965.r001</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Flynn</surname><given-names>JoAnne L</given-names></name><role>Section Editor</role></contrib><contrib contrib-type="author"><name><surname>Boshoff</surname><given-names>Helena Ingrid</given-names></name><role>Associate Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2021 Flynn, Boshoff</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Flynn, Boshoff</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.ppat.1009965" id="rel-obj001" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">12 Aug 2021</named-content>
</p><p>Dear Dr. Behr,</p><p>Thank you very much for submitting your manuscript "Efficacy of epetraborole against&#x000a0;Mycobacterium abscessus&#x000a0;is increased with norvaline" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.</p><p>There are quite a substantial number of concerns, and for some, the authors may already have the data. Nevertheless, the concerns seem feasible enough to address as a minor revision.</p><p>Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.</p><p>When you are ready to resubmit, please upload the following:</p><p>[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript.</p><p>Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out</p><p>[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).</p><p>Important additional instructions are given below your reviewer comments.</p><p>Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.</p><p>Sincerely,</p><p>Helena Ingrid Boshoff</p><p>Associate Editor</p><p>PLOS Pathogens</p><p>JoAnne Flynn</p><p>Section Editor</p><p>PLOS Pathogens</p><p>Kasturi Haldar</p><p>Editor-in-Chief</p><p>PLOS Pathogens</p><p>&#x0200b;<ext-link xlink:href="http://orcid.org/0000-0001-5065-158X" ext-link-type="uri">orcid.org/0000-0001-5065-158X</ext-link></p><p>Michael Malim</p><p>Editor-in-Chief</p><p>PLOS Pathogens</p><p>
<ext-link xlink:href="http://orcid.org/0000-0002-7699-2064" ext-link-type="uri">orcid.org/0000-0002-7699-2064</ext-link>
</p><p>***********************</p><p>There are quite a substantial number of concerns, and for some, the authors may already have the data. Nevertheless, the concerns seem feasible enough to address as a minor revision.</p><p>Reviewer Comments (if any, and for reference):</p><p>Reviewer's Responses to Questions</p><p>
<bold>Part I - Summary</bold>
</p><p>Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.</p><p>Reviewer #1:&#x000a0;The manuscript entitled "Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline" by Sullivan, describes the activity of epetraborate and norvaline against M. abscessus. Overall the paper is very interesting and generally well supported by experimental results. I think this paper could strongly benefit from enzymatic data. Structures look very good and support the results of the paper. There are several issues that should be addressed before the paper can be accepted.</p><p>1. The beginning of the abstract needs to be rewritten. The first few sentences are short and seem disjointed. It reads more like bullet points.</p><p>2. Line 103 &#x02013; The authors used two different methods to measure viability in their whole cell active compound screen, namely luminescence and resazurin. I think it would be helpful to show the correlation between these two screens. I do not believe it changes validity of results, but it would be good to know how many compounds were active on luminescence, resazurin or both.</p><p>3. Line 114 &#x02013; The author claims that EPT lost potency in cation-adjusted Muller Hinton. This seems like an important finding. I believe the authors would make a stronger statement if they could at least provide a at least some speculation on mode of action of EPT.</p><p>4. Line 144 &#x02013; The author reference fig 1C. I found this figure to be challenging to navigate, due to the number of experiments being shown in each panel (MIC of EPT and CLR, with incubation on EPT or CLR, with and without Passage for 6 days). I found myself constantly having to go back to the legend when trying to compare datasets. I think it may be beneficial to split this figure in more panels to make it easier to understand</p><p>5. Fig 1C &#x02013; on the 14 day figure, it seems like pre exposure to EPT, sensitized cells to both EPT and CLR. Especially when comparing the with and without 6 days of passage. The fold change is not large, but the small error bars for these data sets suggest it is statistically significant. Biological significance is however debatable.</p><p>6. Line 154 &#x02013; The authors found no synergy between EPT and other antimycobacterial drugs, yet the text reads &#x0201c;indicating the potential for a future multidrug regime&#x0201d;. I understand they are mostly pointing out that EPT is at least not antagonistic, but I don&#x02019;t know if these results demonstrate strong potential for combination therapy.</p><p>7. Line 161 &#x02013; Wrong figure name. I believe this should be Fig 2A not 1A</p><p>8. Line 167 &#x02013; The authors claim that there was only minimal benefit at 10ug/mL, but significantly improved at 40ug/mL. However, at day 11, the probability of survival is the same in both dosages. Significantly higher than untreated. Please explain.</p><p>9. Fig 2B &#x02013; I believe this experiment should have been carried out longer. Although the 10ug trace started off closely matching the untreated, they separate in the later days. The authors repeatedly mention that abscessus is notoriously difficult to treat, with regimen taking 18 months, yet stopped recording data 11 days post infection. Zebrafish can live for 3 years. Furthermore at 11 days, survivability was still 40% in the untreated cohort, and was not showing sign of plateauing.</p><p>10. Line 185 &#x02013; The authors conclude that the mechanism of resistance must be specific to EPT. However, they only test 3 other drugs. Although it is true that this seems EPT dependent, testing 3 other compounds, with unrelated mechanisms of action, is in my opinion not enough to say it is EPT specific.</p><p>11. Line 186 &#x02013; The authors decided to use a focused approach to identify the mutation in leuS based on literature. However, with only 4 four mutants, I think doing whole genome sequence would have been feasible. It is entirely possible that each mutant had to accumulate more than the D436H mutation. Since the resistance frequency is higher than expected, this is a possibility.</p><p>12. Fig 3c &#x02013; WT cells can become resistant by transforming with a mutant leuS, indicating the enzyme plays a role in the mechanism of resistance. However, the level of resistance is intermediate. I think this should be addressed in the paper to offer some hypotheses. Relative expression of WT leuS vs Mutant leuS in this strain could also explain the results. It is also possible the resistant mutant strain has other mutation contributing to the resistance.</p><p>13. Line 215 &#x02013; The authors hypothesize that EPT is more potent against M. abscessus than M. tuberculosis because it has higher affinity to LeuRS active site in M. abscessus. Binding data does not strongly support that this is the case. However, in order to demonstrate stronger inhibition of the M. abscessus enzyme, I believe an enzymatic assay would be very important. The difference in whole cell potency between species could easily be due to difference in cell permeability, efflux pump or many other cellular processes that can affect potency of drugs. Aminoacyl-tRNA synthetase can be easily assayed by measuring released pyrophosphate or AMP.</p><p>14. PDB- 7N12 I could not access the structure however, the I/sigma is, I believe, too low in the PDB validation document at 0.2. I believe resolution should be cut.</p><p>15. Line 252 &#x02013; Their final conclusion based on structure data seem to contradict their hypothesis that EPT has higher affinity for the M. abscessus enzyme. If this is the case, I believe authors should reflect back on the hypothesis of line 215.</p><p>16. Line 317 &#x02013; Using Norvaline in order to reduce resistance is, in my opinion, very clever. However, I believe that in order to further demonstrate this as a possible avenue, the authors should either demonstrate themselves or provide evidence from literature that Norvaline is safe.</p><p>17. Line 337 &#x02013; The authors are trying to make the argument that using Norvaline in combination with EPT would be valuable, because rapid emergence of resistance caused EPT not to progress in phase 2 clinical study (UTI). However, this contradicts their previous findings, where they claim that resistance rates were lower than expected in M. abscessus. The UTI trial was probably on a different organism, therefore emergence of resistance may not be a problem for treatment of m. abscessus.</p><p>18. Line345 &#x02013; I do not think the enthalpy difference is strong enough to convincingly claim that EPT inhibits M. abscessus&#x02019; LeuRS more than Mtb&#x02019;s. This needs to be assayed enzymatically.</p><p>Reviewer #2:&#x000a0;I thought this was a good manuscript covering an important area of drug discovery for this unmet medical need. A large number of experiments have been performed and the article tells a very complete story. I would support acceptance of this manuscript with a few minor revisions highlighted below</p><p>Reviewer #3:&#x000a0;This well written manuscript describes a series of experiments that identified EPT as a potent inhibitor of Mycobacterium abscessus, confirmed the expected targeting of LeuRS, demonstrated therapeutic proof of concept in a mouse model of M. abscessus infection and tested the novel hypothesis that adjunctive norvaline could potentiate EPT efficacy and suppress emergence of EPT resistance by compromising survival of EPT-resistant LeuRS editing domain mutants. The authors conclude that the approach of combining oxaborole LeuRS inhibitors with leucine mimics hold promise for treatment of M. abscessus infections and potentially tuberculosis and other NTM infections.</p><p>The work is novel, comprehensive and potentially impactful for several difficult-to-treat mycobacterial infections. In addition to EPT, the oxaborole LeuRS inhibitor GSK3036656 has progressed to a phase 2 trial for tuberculosis. A few major and minor issues are described in the comments below.</p><p>**********</p><p>
<bold>Part II &#x02013; Major Issues: Key Experiments Required for Acceptance</bold>
</p><p>Please use this section to detail the key new experiments or modifications of existing experiments that should be <underline>absolutely</underline> required to validate study conclusions.</p><p>Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".</p><p>Reviewer #1:&#x000a0;(No Response)</p><p>Reviewer #2:&#x000a0;None</p><p>Reviewer #3:&#x000a0;The conclusion that the additive activity of norvaline and EPT observed in vivo is attributable to suppression of LeuRS mutants by the addition of norvaline is dubious. Given the extremely low frequency of spontaneous mutants observed in vitro, the limited growth of the bacteria in vivo and the limited bactericidal effect of EPT, these mutants are unlikely to have replaced the susceptible bacterial population in the lungs of mice after just 10 days of treatment. Thus, selective amplification of such mutants is unlikely to be the factor limiting the magnitude of the EPT effect in this model. This could be confirmed by testing the isolates obtained at the end of treatment for EPT resistance and LeuRS mutations. This comment is not intended to discount the observation of potentiation by norvaline but, rather, to challenge the proposed explanation. The proposed experiment could be avoided if the discussion is revised accordingly.</p><p>**********</p><p>
<bold>Part III &#x02013; Minor Issues: Editorial and Data Presentation Modifications</bold>
</p><p>Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.</p><p>Reviewer #1:&#x000a0;(No Response)</p><p>Reviewer #2:&#x000a0;Abstract, summary statement AND introduction should be reviewed to improve the flow of the text</p><p>The location of the resistant mutation (D436H) should be related to those seen in the clinical resistance in E.coli. In particular in relation to whether the same residues are seen and propose how the mutation causes resistance (in the crystallography section)</p><p>Is reference 40 the correct reference for 2mM in vivo treatment of norvaline, if it is then it needs to be made clear this its activity is not for mycobacterial infection models.</p><p>An explanation needs to proposed for why in vivo synergy is seen, I am not an expert in this area but in a study this short it seems unlikely to me that when there is no effect on MIC, synergy would be related to effects on escape resistance when only infecting with 106 bacteria and frequency of resistance is only 2 x-9</p><p>There are two publications this year relating to M abscessus and epetraborole. While this manuscript expands on these studies by looking at norvaline it should mention these earlier publications</p><p>Reviewer #3:&#x000a0;The prospects for incorporating norvaline into clinical use for the adjunctive treatment of mycobacterial treatment could be discussed in more detail. For example, what is the relevance of the 5 mM concentration/dose tested in vitro and in vivo in light of what is known of the human exposures that may be safely attained and tolerated?</p><p>EPT concentrations are alternately described in uM or ug/ml in different sections of the manuscript; one unit should be adopted throughout, with the translation of uM to ug/ml encouraged if uM is used</p><p>Lines 157-70: in this paragraph, figs referenced should be figs 2a-d rather than figs 1a-d</p><p>Line 322: suggest revision to &#x0201c;~10X MIC90 in vitro against the D436H mutant&#x0201d; or something similar to clarify this MIC is against the mutant</p><p>Line 323: suggest revision to &#x0201c;effective in vivo as a neuroprotective agent&#x0201d; or something similar to clarify that this statement of efficacy applies to a different, non-infectious disease model</p><p>Line 386: please indicate which strain was engineered for luminescence</p><p>Lines 752-4: duplicate of ref 30</p><p>Lines 811-3: duplicate of ref 26</p><p>Fig 1 legend: for fig 1c, change &#x0201c;upper&#x0201d; and &#x0201c;lower&#x0201d; to &#x0201c;left&#x0201d; and &#x0201c;right&#x0201d;</p><p>**********</p><p>PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plospathogens/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p><p>Reviewer #1:&#x000a0;No</p><p>Reviewer #2:&#x000a0;No</p><p>Reviewer #3:&#x000a0;No</p><p>Figure Files:</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link xlink:href="https://pacev2.apexcovantage.com" ext-link-type="uri">https://pacev2.apexcovantage.com</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <email>figures@plos.org</email>.</p><p>Data Requirements:</p><p>Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <ext-link xlink:href="http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5" ext-link-type="uri">http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5</ext-link>.</p><p>Reproducibility:</p><p>To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols</ext-link></p><p>References:</p><p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript.&#x000a0;If you need to cite a retracted article, indicate the article&#x02019;s retracted status in the References list and also include a citation and full reference for the retraction notice.</p></body></sub-article><sub-article article-type="author-comment" id="ppat.1009965.r002"><front-stub><article-id pub-id-type="doi">10.1371/journal.ppat.1009965.r002</article-id><title-group><article-title>Author response to Decision Letter 0</article-title></title-group><related-article ext-link-type="doi" xlink:href="10.1371/journal.ppat.1009965" id="rel-obj002" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">10 Sep 2021</named-content>
</p><supplementary-material id="ppat.1009965.s013" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Revewier comments with answers and edits.docx</named-content></p></caption><media xlink:href="ppat.1009965.s013.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></body></sub-article><sub-article article-type="editor-report" id="ppat.1009965.r003" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.ppat.1009965.r003</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Flynn</surname><given-names>JoAnne L</given-names></name><role>Section Editor</role></contrib><contrib contrib-type="author"><name><surname>Boshoff</surname><given-names>Helena Ingrid</given-names></name><role>Associate Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2021 Flynn, Boshoff</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Flynn, Boshoff</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.ppat.1009965" id="rel-obj003" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">23 Sep 2021</named-content>
</p><p>Dear Dr. Behr,</p><p>We are pleased to inform you that your manuscript 'Efficacy of epetraborole against&#x000a0;Mycobacterium abscessus&#x000a0;is increased with norvaline' has been provisionally accepted for publication in PLOS Pathogens.</p><p>Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.</p><p>Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.</p><p>IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.</p><p>Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.</p><p>Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.</p><p>Best regards,</p><p>Helena Ingrid Boshoff</p><p>Associate Editor</p><p>PLOS Pathogens</p><p>JoAnne Flynn</p><p>Section Editor</p><p>PLOS Pathogens</p><p>Kasturi Haldar</p><p>Editor-in-Chief</p><p>PLOS Pathogens</p><p>&#x0200b;<ext-link xlink:href="http://orcid.org/0000-0001-5065-158X" ext-link-type="uri">orcid.org/0000-0001-5065-158X</ext-link></p><p>Michael Malim</p><p>Editor-in-Chief</p><p>PLOS Pathogens</p><p>
<ext-link xlink:href="http://orcid.org/0000-0002-7699-2064" ext-link-type="uri">orcid.org/0000-0002-7699-2064</ext-link>
</p><p>***********************************************************</p><p>The authors have addressed the reviewers' concerns. They were unable to express enzymatically active LeuRS. The measurement of inhibition of the enzyme would certainly have yielded interesting results but do not contribute the major findings of this work.</p><p>Reviewer Comments (if any, and for reference):</p></body></sub-article><sub-article article-type="editor-report" id="ppat.1009965.r004" specific-use="acceptance-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.ppat.1009965.r004</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Flynn</surname><given-names>JoAnne L</given-names></name><role>Section Editor</role></contrib><contrib contrib-type="author"><name><surname>Boshoff</surname><given-names>Helena Ingrid</given-names></name><role>Associate Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2021 Flynn, Boshoff</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Flynn, Boshoff</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.ppat.1009965" id="rel-obj004" related-article-type="reviewed-article"/></front-stub><body><p>
<named-content content-type="letter-date">6 Oct 2021</named-content>
</p><p>Dear Dr. Behr,</p><p>We are delighted to inform you that your manuscript, "Efficacy of epetraborole against&#x000a0;&#x0003c;/i&#x0003e;Mycobacterium abscessus&#x0003c;/i&#x0003e;&#x000a0;is increased with norvaline," has been formally accepted for publication in PLOS Pathogens.</p><p>We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.</p><p>The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.</p><p>Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.</p><p>Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens. </p><p>Best regards,</p><p>Kasturi Haldar</p><p>Editor-in-Chief</p><p>PLOS Pathogens</p><p>&#x0200b;<ext-link xlink:href="http://orcid.org/0000-0001-5065-158X" ext-link-type="uri">orcid.org/0000-0001-5065-158X</ext-link></p><p>Michael Malim</p><p>Editor-in-Chief</p><p>PLOS Pathogens</p><p>
<ext-link xlink:href="http://orcid.org/0000-0002-7699-2064" ext-link-type="uri">orcid.org/0000-0002-7699-2064</ext-link>
</p></body></sub-article></article>